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Abstract 
 
The overarching objective of this work centers on a structure-function approach to 
investigate the mechanism of action of synthetic copolymer-based membrane 
stabilization in the context of Duchenne Muscular Dystrophy (DMD). The guiding theme 
is the investigation of mechanism of interaction of membrane stabilizing copolymers 
using cellular and whole animal physiology, chemical engineering, and 
supercomputational approaches. 
DMD is an X-linked recessive disease of marked striated muscle deterioration 
affecting 1 in 3500-5000 boys. DMD results from the lack of the cytoskeletal protein 
dystrophin, which is essential for maintaining the structural integrity of the muscle cell 
membrane. DMD patients develop severe skeletal muscle degeneration, along with 
clinically significant cardiomyopathy. There is no cure for DMD patients, or any 
effective treatment to halt, prevent or reverse DMD striated muscle deterioration. The 
primary pathophysiological defect in DMD is the marked susceptibility to contraction-
induced membrane stress and the subsequent muscle damage and degeneration that 
occurs due to loss of muscle membrane barrier function. In this context, a unique 
therapeutic approach is the use of synthetic membrane stabilizers to prevent muscle 
damage by directly stabilizing the dystrophin-deficient muscle membrane. The triblock 
copolymer poloxamer 188 (P188) has numerous features that make it an attractive 
synthetic membrane stabilizer candidate for DMD treatment and has been demonstrated 
to target and stabilize damaged membranes in various pathophysiological contexts.  
The efficacy of P188 in protecting the dystrophic myocardium has been well 
established, but its effect on the dystrophic skeletal muscle has remained unclear. This 
work for the first time demonstrates that P188 stabilizes the dystrophic skeletal muscle 
membrane in vivo and protects it against the mechanical stress associated with 
lengthening contractions. This result validates P188 as a therapeutic strategy to directly 
target the hallmark of DMD: impaired membrane stability in all striated muscles.  
  v 
Very little is known on how P188 interacts with and stabilizes biological 
membranes. To fundamentally probe the mechanism of action of synthetic copolymers as 
membrane stabilizers, a structure-function approach was undertaken.  The aim was to 
gain insight into the essential critical chemical parameters of copolymers in terms of 
membrane interacting properties. This work shows for the first time that copolymer mass, 
composition, architecture, and functional end group chemistries significantly define 
mechanism of action at the membrane. Based on these insights, an “anchor and chain” 
model is advanced whereby membrane interaction is critically dependent on end group 
hydrophobicity.  
Finally, leveraging the power of supercomputational approaches, Molecular 
Dynamics simulations were developed to further evaluate and understand copolymer-
membrane interactions at atom level resolution.  Using increases in surface tension 
applied to the lipid bilayer, an area-per- lipid dependence of adsorption vs. insertion was 
uncovered, supporting the hypothesis that copolymers insert into areas of decreased lipid 
density and then are “squeezed-out” once membrane integrity is restored.   Collectively, 
these findings shed new light on block copolymer dynamic interaction with biological 
membranes. 
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CHAPTER 1 
INTRODUCTION 
 
 
Overview 
 
 The central focus of this dissertation is the investigation of copolymer-based 
membrane stabilizers to protect striated muscle membranes against the mechanical forces 
associated with contraction in the context of Duchenne Muscular Dystrophy (DMD). The 
purpose of this chapter is to describe DMD and the role of dystrophin, as well as 
introduce a potential synthetic copolymer-based therapeutics to the disease.  
 
 
1.1 Duchenne Muscular Dystrophy 
 
 Duchenne Muscular Dystrophy is an X-linked neuromuscular disease of muscle 
degeneration which results from the lack of the dystrophin protein at the muscle 
membrane (sarcolemma)
1
. It was first described in 1852 by Meryon and later by 
Duchenne in 1868
2
.  As the most common of the human muscular dystrophies, it affects 1 
in 3500 males every year
3
 or ~20 000 new patients worldwide each year, with typical 
onset between the ages of 2 and 5 years that is characterized by delay in achieving 
childhood motor milestones. The disease presents as a prominent and progressive 
weakness in the lower limbs muscles and postural muscles
4
, leading to spinal scoliosis, 
and decrease in exercise capacity. Weakness of the knees and hip extensors are displayed 
through the Gower's sign, a maneuver through which the affected child will right himself 
from a supine position by using his hands and arms to extend the hips and bring the torso 
to an upright position
5
. Other physical symptoms include reduced muscle bulk, pseudo-
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hypertrophy and contractures of the calf muscles and joints
6
. Bone fragility and 
osteoporosis also contribute to the development of scoliosis
7
.  
Concurrent with the decline in orthopedic condition is loss of respiratory function 
brought on by significant diaphragm wasting
8
 leading patients to be placed on positive 
pressure nocturnal ventilation. Current clinical diagnosis is made via genetic testing to 
probe for absence of the dystrophin protein or mutation in dystrophin gene, as well as 
measurements of plasma levels of creatine kinase (CK)
9,10
, a striated-muscle specific 
enzyme marker of membrane damage. Loss of ambulation and wheelchair dependency 
occur by their early teens
11
, and patients typically succumb in their late second decade of 
life due to respiratory failure.   
In addition to the skeletal muscle pathology, DMD patients also develop 
progressively severe cardiomyopathy, with 10-20% of cases presenting as dilated 
cardiomyopathy
12
 with arrhythmias and eventually heart failure occurring in the latter 
half of the second decade of life
11
. With increases in patient lifespan as a result of 
palliative glucocorticoid treatment and improvements in respiratory care and orthopedic 
corrections
9,13
, cardiomyopathy is an increasingly important but underappreciated 
contributor to DMD mortality despite cardiomyopathy being present in 90% of DMD 
patients by age 18 and confirmed by the finding of significant myocardial fibrosis in 
autopsies
14–17
.  Interestingly, the cardiomyopathy usually remains subclinical at early age 
and cardiac disease progression typically proceeds at a slower rate compared to the 
skeletal muscle degeneration
18
. The incidence and evolution of cardiomyopathy in 
Duchenne muscular dystrophy is presumably due to lesser strain on the heart when 
physical activity is limited once the patient is wheelchair bound. Clinical symptoms 
include rhythmic, structural and hemodynamic abnormalities with defects in both systolic 
and diastolic functions
19
. Electrocardiography reveals some electrical conduction 
impairment such as sinus tachycardia, premature atrial contractions and fast 
atrioventricular node conduction
11
. 
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Gastrointestinal manifestations related to smooth muscle dysfunction also occur 
more commonly as a secondary pathology to respiratory infection, cardiac failure or 
recent surgery although spontaneous smooth muscle dysfunction has been observed in the 
latter stages of the disease
11
. Smooth muscle of the gastrointestinal tract of DMD patients 
show both loss and atrophy and fibrosis
11
. 
Cognitive impairment is also seen in varying degrees in DMD patients indicating 
that dystrophy affects brain function although the impairment is neither progressive nor 
correlated with the severity of the musculoskeletal symptoms
20
. Boys with DMD have 
been observed to perform more poorly on tests requiring attention to complex verbal 
information and the mean IQ for DMD patients is one standard deviation below normal, 
with 1/3 patients having an IQ below 75.  The causes of the IQ impairment remains 
unclear although studies have revealed abnormal dendritic development and arborisation 
of nerve axons branching
21
.  
 
 
1.2 Dystrophin 
 
Extensive genetic analysis of DMD patients determined that disruption of the 
dystrophin gene is causal for the disease
1
. Dystrophin is the largest discovered human 
gene and is located on the short arm of the X-chromosome, consists of 79 exons and is 
over 2.3 million base pairs in size. It also has one of the highest known spontaneous 
mutations rates of all human genes. There are three full-length isoforms with three 
different promoters in striated muscle, brain and cerebellar Purkinje neurons. Other 
isoforms are generated via alternative splicing events
22
. The dystrophin gene has four 
internal promoters, dp260, dp140, dp116 and dp71 that have tissue specific 
expressions
1,23
. Deletion of one or more exons is the most common defect in the DMD 
gene, with duplications, point mutations (missense, nonsense, and splice site variations) 
and rearrangement (insertions, deletions or inversion) being less common defects. While 
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the vast majority of DMD mutations results in the complete absence of dystrophin, 
certain mutations result in low levels of a truncated but partially functional dystrophin 
protein with individuals affected by a milder form of the disease (Becker muscular 
dystrophy).  
The dystrophin protein is a 427 kDa, 3685 amino acids rod-shaped cytoskeletal 
protein found on the intracellular surface of the muscle membrane that links cytoskeletal 
γ-actin to the extracellular matrix.  Dystrophin consists of four major functional domains: 
an actin-binding domain at the N-terminus, a central rod domain consisting of 24 
spectrin-like repeats separated by four hinge regions, that has been shown to unfold and 
give flexibility in response to mechanical stretch
24
, a cysteine-rich domain that interacts 
with the transmembrane protein β-dystroglycan, and a C-terminal domain, the latter being 
important for dystrophin’s interaction with other sub-sarcolemmal proteins. Carefully 
designed transgenic studies have determined that the domains most critical to the DMD 
pathology are the cysteine-rich domain and the N-terminal domain, which are those 
directly associated with mechanically linking the extracellular matrix and the 
cytoskeleton
25
.   
Dystrophin is part of a large membrane-spanning complex of glycoproteins 
(Dystrophin-Glycoprotein complex or DGC) that also include sarcoglycans (α, β, γ, δ), 
dystroglycans (α and β), dystrobrevins, syntrophins and sarcospan (Figure 1).  The 
essential function of dystrophin in striated muscle is to stabilize the muscle membrane 
against the forces associated with contraction thereby acting as a "molecular shock 
absorber" or molecular force dampener of the muscle membrane.  
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Figure 1: Dystrophin-glycoprotein complex (DGC) at the sarcolemma.   
 
Loss of dystrophin affects many aspects of muscle function and the precise 
molecular mechanisms leading to membrane injury and muscle degeneration is not fully 
resolved. The importance of dystrophin's molecular reinforcement at the membrane is 
evident in studies showing that dystrophin-deficient muscle fibers where the membrane 
was experimentally removed show no difference in contractile function compared to 
normal skeletal muscle fibers, indicating a defect in the membrane-cytoskeleton linkage 
rather than in the contractile apparatus
27
.  The DGC is found to be enriched at the 
costamere, a sub-sarcolemmal protein complex which assembles at regular intervals 
along the sarcomere and stabilizes the cytoskeletal apparatus via the intermediate 
filament network through the membrane, to the extracellular matrix
28,29
. In cardiac 
myocytes, dystrophin appears to also co-localize with t-tubules
30
. Dystrophin is crucial 
for maintenance of the DGC in skeletal muscle
31
, the lack of dystrophin leading to 
marked reduction of all DGC components at the sarcolemma. In contrast and for unclear 
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reasons, DGC expression is not significantly affected by loss of dystrophin in cardiac 
muscle
32
.   
Dystrophin plays a critical role mechanically linking the extracellular matrix to 
the sarcomeres and the extracellular matrix transmits the force generated at the 
sarcomeres to the muscle tendon
33–35
.  In striated muscle, force is transmitted laterally 
from the Z-discs at the sarcomere through the membrane to the extracellular matrix
33,36
. 
These studies suggest that force is lost during transmission from cell-to-cell independent 
of loss in membrane integrity
37,38
. 
 Dystrophin has a homolog protein, utrophin, with which it shares significant 
sequence and structural homology
39
. While utrophin is not part of the DGC complex 
itself, it is highly expressed in muscle during development but its expression becomes 
restricted to only the neuromuscular junction and myotendinous junctions in normal adult 
skeletal muscle.  However, utrophin expression has been found to be upregulated at the 
sarcolemma along the entire myofiber and was found to mitigate the severity of the 
pathogenesis in some DMD animal models, suggesting that this adaptation is beneficial 
and leading to the proposition of utrophin upregulation as a potential therapeutic goal for 
DMD. 
In addition to mechanical and anchoring roles, DGC members also act as 
scaffolding proteins for various signaling pathways. Syntrophins, which bind to 
homologous sequences in the C-terminal domain of dystrophin, contain a PDZ domain 
which recruits nitric oxide synthase (nNOS), aquaporin-4, diacylglycerol kinase-ζ, and 
various ion channels to the DGC.  Here nNOS is of particular interest in DMD as a well-
known signaling molecule involved amongst other cellular processes, in the regulation of 
blood flow to skeletal muscle by synthesizing nitric oxide from the oxidation of L-
arginine to L-citrulline.  Nitric oxide diffuses to vascular smooth muscle cells and 
opposes exercise-induced α-adrenergic constriction and this process was found to be 
impaired in DMD
40
. Effectively, nNOS is lost from the sarcolemma when dystrophin is 
absent and is reduced in both total content and activity
41,42
. As such, dystrophic skeletal 
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muscle is susceptible to ischemic insults, and therefore decreased perfusion, during 
contractile events
43
.  Moreover, nNOS is expressed at high level in fast type II skeletal 
muscle fibers which may explain the increased susceptibility of this fiber type to injury in 
DMD
44
.  These results point to a deleterious effect of unopposed adrenergic 
vasoconstriction on dystrophic muscle perfusion both in terms of energetic depletion due 
to ischemia as well as restricted perfusion of potential therapeutics to affected muscles. 
 
 
1.3 Muscle mechanics 
 
1.3.1 Muscle structure 
 
 Skeletal muscles are made up of myofibers, which themselves contain bundles of 
myofibrils made up of proteins including actin and myosin filaments arranged in repeat 
myofilament units named sarcomeres. The arranged repetitive units of sarcomeres along 
the length of the myofibril give skeletal muscles their characteristic striated appearance. 
The functional unit of the myofibril is named a sarcomere, which consists of thick 
filaments made up of the protein myosin and thin filaments made up of actin. The 
globular heads on myosin are also known as cross-bridges as their role is to bind and pull 
actin thin filaments past the thick filament in what is known as the sliding filament 
mechanism of muscle contraction. 
 
1.3.2 Excitation-contraction coupling 
 
 At the initiation of contraction, electrical impulses are transmitted from nerve 
terminal endings of motor neurons to the motor end plates of muscle fibers. This causes 
depolarization of the cell membrane and propagation of the action potential through the 
transverse tubule system leading to activation of voltage-gated Ca
2+
 channels and release 
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of Ca
2+
 from the sarcoplasmic reticulum (SR) of the muscle cell.  This leads to a transient 
increase in cytoplasmic Ca
2+
, activation of the contractile apparatus, and generation of 
muscle tension.  This process linking the depolarization of the muscle sarcolemma to the 
release of Ca
2+
 from the sarcoplasmic reticulum (SR) of the muscle cell is referred to as 
excitation-contraction (EC) coupling
45
.  EC coupling differs between skeletal and cardiac 
muscle.  In skeletal muscle, the action potential passes along the sarcolemma and into the 
sarcolemmal invaginations of the t-tubule system. Depolarization is sensed by voltage-
sensitive Ca
2+
 channels, the dihydropyridine receptor (DHPR), which isoforms differ 
between cardiac and skeletal muscle. The skeletal muscle DHPR only mediates a small 
influx of extracellular Ca
2+
 and activates Ca
2+
 release from the SR via direct mechanical 
coupling with the ryanodine receptor type 1.   In contrast, in a cardiac muscle cell, the 
extracellular Ca
2+
 flowing through the DHPR binds to and activates the ryanodine 
receptor type 2 on the SR, leading to Ca
2+
  release from the SR in a "Ca
2+
  induced Ca
2+
  
release" process.  
 At resting intracellular Ca
2+
 concentrations, the contractile apparatus remains in 
an inactivated state in which myosin heads on the thick filaments cannot bind actin on the 
thin filaments due to tropomyosin interacting with and blocking actin-myosin binding 
sites on actin. Upon SR Ca
2+
 release, the resulting rise in cytoplasmic Ca
2+ 
leads to Ca
2+
  
binding to troponin C, the sensory component of the three part protein complex troponin, 
on the thin filaments which then allosterically moves tropomyosin to reveal the myosin 
binding sites on actin. Myosin heads then bind actin and initiate the ATP-dependent 
cross-bridge cycling process which is the basic process for muscle force production and 
contraction. 
  
1.3.3 Types of muscle contractions 
 
 Excitation-contraction coupling leads to a twitch response from muscle units and 
the contraction of whole muscle groups is derived from both temporal and spatial 
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summation of single twitches. Repeated and rapid stimuli create a maximal sustained 
contraction called tetanus. There are three types of muscle contractions: shortening (or 
concentric), isometric, and lengthening (or eccentric).  Shortening contractions occur 
when the force produced by the muscle exceeds the force applied to the muscle resulting 
in shortening of the muscle. Isometric contractions are characterized by constant muscle 
length during activation, with the force generated dependent on the muscle length at time 
of activation. Maximal isometric force is generated at the muscle optimal length (Lo) 
where the maximum numbers of cross bridges are available. Lengthening contractions 
occur when the force applied to the muscle exceeds the force generated by the muscle, 
resulting in lengthening of the muscle.  Repetitive lengthening contractions can cause 
damage to myofibers by injuring elements of the EC coupling machinery
36,46
.  
 
 
1.4 Cell membrane structure, function, and susceptibility to mechanical injury 
 
1.4.1 Biological lipid membranes 
 
Biological membranes are asymmetrical bilayers approximately 5-6 nm thick and 
composed of various lipids including phospholipids, sphingolipids, glycolipids and 
sterols, with compositions varying between different cell types and in diseased states. The 
cell membrane is also typically composed of 20-30% proteins responsible for ion 
conduction, various signaling pathways, and structural integrity
47
. Regardless of the cell 
type and function, the primary role of the cellular membrane is to segregate the 
intracellular milieu from the outside environment to actively preserve intracellular 
homeostasis.  Its constituent proteins are essential for normal transmembrane passage of 
ions, allowing maintenance of physiological ionic gradients at affordable metabolic cost. 
Failure to maintain this barrier function leads to exhaustion of the metabolic energy of the 
cell, biochemical arrest, and eventual cellular demise. The membrane bilayer is held 
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together via hydrophobic effect with the surrounding polar environment as well as van 
der Waals forces, hydrogen bonding, and electrostatic interactions. Membrane  
constituents are allowed various intra-bilayer motions, such as lateral diffusion, rotation 
of lipids around their major axes, and oscillations
48–50
.  These motions as well as degree 
of packing the bilayer components are collectively described as "membrane fluidity"
48
, 
which is modified by a number of factors such as lipid composition, sterol enrichment, 
and temperature, and which is commonly assessed using fluorescence polarization 
methods, electron spin resonance and other spectroscopic methods
51–54
.  It has been 
proposed that lipid fluidity and membrane conformation influences the activity and 
dynamics of membrane proteins
52
. Along with membrane fluidity, the structure and 
composition of the bilayer can be described by parameters such as rigidity, elasticity, and 
tensile strength, all of which make up the membrane physical property known as plasma 
membrane order
50,55
.  Data from various studies have proposed that an optimal level of 
membrane order is essential for normal myocyte function
49,56
.  Of particular interest to 
muscle, nicotinic acetylcholine receptors (nAChRs), which are present at neuromuscular 
junctions of muscle cells, require optimal membrane order to retain normal function
57
 and 
alterations to the membrane either during mechanical stress or in diseased states such as 
in DMD could have important ramifications on action potential generation and 
propagation during muscle contraction.   
  
1.4.2 Membrane permeability and mechanical injury in DMD 
 
 Electron microscopy analysis of DMD muscle revealed absent or disrupted 
sections of the muscle membrane thereafter named delta lesions
58,59
.  This led to the 
theory that the loss of dystrophin and associated proteins at the sarcolemma renders the 
muscle susceptible to muscle contraction-induced injury. Indeed, the finding of the 
soluble enzyme creatine kinase released from the injured muscle into the serum is a 
clinical hallmark of the disease
60
. Moreover, the ongoing degeneration-regeneration 
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process leads to satellite cells exhaustion and replacement of muscle with fibrotic and 
fatty connective tissues leaving small islands of intact muscle cells. The membrane 
permeability associated with the lack of dystrophin leads to loss of homeostasis within 
the cell, with influx of ions such as Ca
2+
 from the extracellular fluid, which in turns 
activates pathological pathways inside the cell such as inflammatory immune cell 
infiltration, cytokines and proteolytic enzyme activation, leading to apoptosis and 
necrosis
61,62
.   
Membrane permeability is further exacerbated by mechanical stress, particularly 
with lengthening contractions of skeletal muscles such as during downhill 
walking/running
34
.  In DMD patients, muscle biopsies reveal ongoing degeneration and 
regeneration of muscle fibers and creatine kinase is persistently elevated. It is unclear 
what the precise nature of membrane disruptions after lengthening contractions look like, 
however, the release of intracellular enzymes such as creatine kinase and the uptake of 
large proteins such as albumin and vital dyes like Procion orange
34
 and Evans blue dye
63
 
into non necrotic muscle fibers indicate that the membrane disruption is sufficiently large 
to permit the transmembrane passage of large macromolecules
60
.  
Lengthening injury is particularly apparent in the diaphragm which contracts to 
expand the lungs during breathing, with ventilatory muscles of DMD animal models and 
patients having impaired contractility and increased fibrosis
64
. Dystrophin also plays a 
crucial role in buffering against cardiac myocyte extension.  This occurs when the 
ventricle fills with blood during diastole, and its absence leads to the formation of small 
membrane tears as evidenced by uptake of extracellular molecules
37
.  Moreover, the 
consequences of membrane disruptions and increased permeability to extracellular ions 
such as Ca
2+ 
are intrinsically different between cardiac and skeletal muscle as the process 
of Ca
2+ 
induced Ca
2+ 
release from the ryanodine receptors is amplified in the heart
65
. As 
such, with increases in contractility and larger passive extensions, subsequently more 
unregulated Ca
2+ 
entry into the cell eventually results in terminal contracture of the 
dystrophic myocyte
37
.          
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Along with its barrier maintaining function, the cell membrane is responsible for 
transmitting and propagating action potentials generated at the neuromuscular junction to 
the transverse tubule (t-tubule). In dystrophic muscles, this network is directly affected by 
lengthening stretches as it runs perpendicular to the axis of contraction and anchors along 
the contractile unit of the muscle (sarcomere)
66
. The t-tubules contain the voltage-gated 
Ca2+ channels required to activate muscle contraction and are required for proper 
propagation of action potentials generating from the nerve terminals to the whole muscle. 
As lengthening stretch disrupts the sarcomeres of weakened muscle membranes, the t-
tubules are also laterally disrupted, affecting electrical conduction during muscle 
contraction.  
 
1.4.3 Calcium homeostasis 
 
 It is strongly suggested that Ca
2+ 
homeostasis may be perturbed in dystrophic 
muscle and that this may be an important initiator of the pathological processes leading to 
muscle cell death. Intracellular calcium levels are reported to be elevated in both mdx 
skeletal muscle fibers and cardiomyocytes
37,67–69
. It is still unclear what causes this rise in 
intracellular Ca
2+
, with some studies suggesting Ca
2+
 entering the cell due to increased 
sarcolemmal permeability or "breaches"
37
, and other studies showing evidence for the 
activation of Ca
2+
 leak channels or stretch-activated channels
70
. Regardless of the initial 
mechanism of entry, this abnormal elevation in Ca
2+
 has consequences to muscle 
structure and function due to activation of pathological Ca
2+
 sensitive cellular pathways 
such as activation of the calpain proteases
71
 and perturbation of calcium-activated 
signaling pathways including calmodulin
72
, calcineurin
73
, and the mitochondrial 
permeability transition
74
. A pathological rise in cytosolic Ca2+ also contributes to 
membrane damage via activation of phospholipase A2 and promotion of reactive oxygen 
species (ROS) production by the mitochondria
75
. ROS in turns leads to peroxidation of 
membrane lipids
76,77
. Consequently, maintaining intracellular Ca
2+
 homeostasis by 
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preventing deleterious influx of extracellular Ca
2+
 is crucial to maintaining sarcolemmal 
integrity and survival of the dystrophic myocyte.  
 
1.4.3 Endogenous cellular membrane repair mechanisms 
  
For pure lipid bilayers such as liposomal and vesicular assemblies, resealing of 
injured bilayers occurs in a spontaneous, thermodynamically driven manner at a rate 
dependent on membrane tension, with higher membrane tension having slower rate of 
repair
78,79
.  On the other hand, the presence of a cortical cytoskeleton in living cells 
results in a baseline surface tension that is not existent in simple lipid bilayers and which 
prevents spontaneous resealing
80,81
. Loss of membrane integrity compromises its function 
in maintaining cellular homeostasis and can lead to the demise of the cell. As membrane 
disruptions are common and normal events in the life of a cell, particularly in muscle 
cells
82
, there must exist an innate repair mechanism to rapidly restore the integrity of the 
cell and prevent cell death.   
It was found that resealing of living cells is immediately preceded by a decrease 
in membrane tension
79
 and absolutely requires Ca
2+
 -dependent exocytosis to deliver 
vesicles to the site of disruption to fuse and form patches
79,83
.  This decrease in membrane 
tension is, at least in part, due to expanding of membrane area by active insertion of 
internal vesicle membrane via exocytosis
82,84
.  The protein dysferlin, which localizes to 
the plasma membrane
85
, has been identified as having a pivotal role in the active 
membrane repair process in cardiac
86
 and skeletal muscle
87
. Dysferlin is thought to 
regulate vesicle trafficking and fusion at the site of membrane injury in a Ca
2+
 dependent 
manner via association with annexins A1 and A2
88,89
 and requires several other proteins 
including SNARE proteins
90
 and synaptotagmins
91
. The absence of dysferlin leads to 
defective membrane resealing and certain types of muscular dystrophy classified as 
dysferlinopathies
92
. Another protein that was discovered to play an important role in 
membrane repair is the TRIM-family E3 ubiquitin ligase protein MG53. MG53 is 
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recruited to the injury site where it is proposed to be oxidized when exposed to the 
oxidative extracellular environment to form a disulfide-linked oligomerized scaffold
93,94
. 
This scaffold then serves as an assembly site to recruit MG53-tethered intracellular 
vesicles toward the injury site for fusion with the damaged membrane
94,95
.  
In DMD, increased susceptibility to membrane tearing eventually leads to cell 
death and muscle degeneration by eventual overwhelming of this cell repair processes
96
. 
Chronic damage resulting from a continual cycle of muscle degeneration and 
regeneration eventually leads to depletion of the skeletal muscle stem cell pool and 
muscle wasting. 
 
 
1.5 Current therapeutic strategies for DMD 
 
1.5.1 Palliative treatments 
 
 There is currently no cure for DMD and while current supportive therapies help 
improve lifespan and quality of life, development of new and improved palliative 
treatments is still critical.  The most commonly prescribed treatments are ventilatory 
support, corticosteroids and β-blockers6,97–99. Nocturnal ventilatory support is provided in 
the earlier stages of the disease, but inevitably becomes constantly required as the disease 
worsens owing to loss of diaphragm function. Ventilatory support has been shown to 
maintain pulmonary function presumably by reducing diaphragm workload and 
significantly prolongs DMD patients' lifespan
8,99,100
.   
Corticosteroids have been used to treat DMD since the mid 1970s
97
 and are the 
current standard therapy for the disease.  Prednisolone and deflazacort are regularly 
administered soon after diagnosis and have been shown to slow the progression of the 
disease by improving muscle strength and exercise capacity thereby delaying loss of 
ambulation and improving both pulmonary and cardiac functions
16,97,101
. Glucocorticoids 
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have been shown to benefit both skeletal and cardiac muscle and while the precise 
mechanism through which corticosteroids improve muscle function remains unclear, it is 
hypothesized that it is beneficial via anti-inflammatory effects, increased expression of 
the dystrophin homolog utrophin, and increased skeletal muscle proliferation
97,98,102
.  
However, chronic corticosteroids use is associated with numerous adverse effects 
including weight gain, gastrointestinal symptoms, behavioral difficulties, cataracts and 
bone demineralization
98,103,104
. Despite the side effects and risks involved with long-term 
chronic use of steroids, corticosteroids continue to be the first-line treatment for DMD.    
For the DMD heart disease, β-blockers are usually prescribed at the first signs of 
cardiomyopathy and in combination with ACE inhibitors have shown to improve left 
ventricular ejection fraction and reduced mortality
105–107. β-blockers prescribed at the 
point of diagnosis as a cardioprotective pretreatment is currently under consideration. 
While these treatments help alleviate symptoms, they do not directly target the disease 
mechanism nor prevent its progression.  
 
1.5.2 Animal models of DMD 
 
 The primary mouse model of DMD, the mdx mouse, was discovered not long 
after the discovery of the dystrophin gene, by the detection of muscle pyruvate kinase and 
creatine phosphokinase in serum in a screen for glycolytic enzyme mutants
108
. This 
mouse model harbors a naturally occurring non-engineered stop codon in exon 23 of the 
dystrophin gene causing the lack of dystrophin in all of its striated muscle. As such, the 
mdx mouse displays most of the hallmarks of DMD including decreased lifespan, muscle 
wasting, progressive cardiomyopathy, fibrosis, and leakage of muscle specific enzymes 
into the serum. However, the mdx mouse has a milder baseline phenotype presumably 
due to compensatory mechanisms in mice such as increased expression of the dystrophin 
homolog utrophin. Mdx mice do show many features of DMD with pathology being most 
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prominent in the diaphragm
64
 where fiber loss and collagen deposition are significant and 
atrophy and fibrosis of limb muscles present in older mdx mice.  
While the mdx phenotype does not fully recapitulate the human disease severity 
under normal conditions, physiological stresses induce significant cardiac and skeletal 
muscle dysfunction in mdx mice
37,34
.  In terms of cardiac function alterations, mdx hearts 
have changes in ventricular geometry with significantly lowered systolic and diastolic 
volumes compared to normal hearts but largely maintain stroke volume
37
. The shift to 
lower volumes is hypothesized to be due to adaptation against the defect in passive 
distention in mdx cardiac myocytes, resulting in a relatively normal baseline cardiac 
function but little cardiac reserve, which is particularly evident during adrenergic stress 
testing
37
. The vast majority of studies have been carried out using this model making it 
the current standard model to evaluate therapeutic efficacy for DMD. More similarly to 
DMD patients, dystrophin/utrophin double knockout mice (mdx:utr
-/-
) have a much more 
catastrophic phenotype at baseline and significantly reduced lifespan, with most dying 
prematurely between 9 and 10 weeks of age, with active degeneration/regeneration, 
widespread inflammation, sarcolemmal leakage and fibrosis starting at ~2 weeks of 
age
109,110
.  
 In addition to the mdx and mdx:utr
-/-
 mice models, several dystrophin-deficient 
dogs have been identified, with the golden retriever muscular dystrophy model (GRMD) 
showing the closest similarity to the human DMD skeletal muscle phenotype as well as a 
profound dilated cardiomyopathy with myocardial wasting, fibrosis, and contractile 
dysfunction 
111–113
. As such, the GRMD is considered the current gold standard large 
animal model for DMD. However, the costs associated with GRMD dogs upkeep and 
care however limits the testing of potential treatments to only those that have passed pre-
clinical efficacy in mdx and mdx:utr
-/-
 mice models.    
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1.5.3 Current therapeutic avenues 
 
Gene-based therapies 
 
 Replacement of dystrophin using viral gene therapy and exon skipping 
approaches are one of the main promising strategies targeted at treating DMD, via aiming 
to restore or complement dystrophin expression. Adeno-associated virus (AAV), which 
benefits include long-term gene expression, high transduction levels in muscle and 
muscle-specific serotypes, has emerged as the current transgene delivery tool of 
choice
114
.  Recombinant AAV (rAAV) vectors however have limited packing capacity 
and the enormous size of the dystrophin cDNA has constrained investigators to perform 
detailed functional analysis of dystrophin structural domains to determine which regions 
can be deleted or recombined without significant consequences to function.  Because 
Becker patients exhibit a milder phenotype and relatively normal lifespan, micro
115,116
 
and mini-dystrophins
24,117,118
 constructs have been generated to mimic BMD deletions to 
render semi-functional dystrophins.  
In addition, as structure-function of dystrophin and particularly, its interactions 
with other components of the DAPC has been uncovered, refinement of these dystrophin 
constructs have allowed to keep functionality of the transgene as close to the full-length 
dystrophin as possible.  In addition to limited packaging size of the delivery vectors, there 
are still many hurdles including immunological barriers to the viral vector and/or the 
transgene, poor delivery to target tissues, and the roadblocks associated with producing 
high enough viral titres for clinical applications
114
.  
 Utrophin, the homolog protein to dystrophin, is also a functional substitute for 
dystrophin and has been shown to be upregulated at the sarcolemma of dystrophic animal 
models
39
.  Over-expression of utrophin or its truncated forms has been shown to 
completely prevent the dystrophic phenotype and is thus another potential therapeutic 
approach under investigation
119–122
. To overcome delivery vectors and immunogenicity 
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complications associated with rAAV delivery of dystrophin, one approach is to increase 
the expression of utrophin gene at a transcriptional level using small molecules such as 
SMTC110 to target already existing cellular mechanisms.  One limitation however is that 
utrophin lacks an nNOS-binding site and is therefore unable to restore nNOS to the 
sarcolemma
123
.  
 For exon skipping, the general strategy is to restore expression of the mutated 
dystrophin gene by skipping frame-disrupting mutations in the dystrophin gene using 
antisense oligonucleotides (AO), short nucleic acid analogues that attach to mRNA or 
single-stranded DNA, with a number of out-of-frame mutations rendered phenotypically 
mild through endogenous exon skipping and other alterations in splicing and post 
transcriptional-translational processing. This process leads to production of truncated but 
functional dystrophins. Exon skipping using small molecules has been demonstrated to 
ameliorate the severe phenotype in both canine and murine DMD models
124–128
 while 
being well tolerated and non-immunogenic but this strategy is only applicable to the 
subset of DMD patients with the corresponding targeted mutation.  
Several phase II/III clinical trials using antisense oligonucleotide (AO)-induced 
exon skipping targeting exon 51 (applicable to 13% of DMD patients) of dystrophin to 
restore its open reading frame have recently completed. Results from a recently 
completed Phase III randomized, double blond, and placebo controlled clinical study of 
Drisapersen. 2’-O-methyl phosphorothioate (2OMePS) AO, did not meet its primary 
endpoint, with no statistical improvement in the Six-Minute Walking Distance (6MWD) 
test in a trial of 186 boys nor improvements in secondary assessments of motor 
function
129–131
.  Moreover, dosage is a limiting factor with Drisapersen, with renal 
toxicity observed at higher dosages
131
, limiting the level of dystrophin production that 
can be achieved. 
In a different trial conducted by Mendell et al. using Eteplirsen, an AO with a 
phosphorodiamidate morpholino (PMO) backbone that induces removal of exon 51 
during the RNA splicing process, systemic delivery to a small cohort of DMD patients 
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resulted in a dose-dependent restoration of dystrophin production with upregulation of 
other dystrophin-associated proteins at the membrane, along with some improvement in 
patient walking ability compared to placebo controls
132,133
.  However, this improvement 
was only observed in a small subset of the patient group, with dystrophin levels observed 
to be highly variable among all patients. Most preclinical studies have reported higher 
efficiency of AOs using the PMO backbone chemistry as well as apparent non-toxicity 
compared to the 2OMePS chemistry
124,127,134
 but there are still concerns about their 
ability to produce a clinically therapeutic amount of dystrophin protein product as well as 
improving tissue targeting efficiency and uptake of AOs, particularly to the diaphragm 
and cardiac muscle.  
 Stop codon read-through using aminoglycosides such as gentamicin restore 
protein translation by causing misreading of the RNA and allowing alternative amino 
acids to insert at the site of the stop codon, with applicability to ~15% of DMD patients, 
but toxicity is a major concern. Other synthetic compounds discovered via screening for 
read-through are currently under evaluation.   
 The DMD gene has one of the highest rates of new mutations, complicating all 
gene targeting approaches that need to be applied to be able to treat all DMD patients. 
Gene editing using endonuclease-mediated gene repair allows for permanent repair of the 
patient’s DNA to restore full-length dystrophin and is therefore applicable to all DMD 
patients regardless of mutation. Gene correction can be achieved using oligonucleotide-
mediated genome repair, spliceosome-mediated RNA trans-splicing, and gene targeting.   
 Another very exciting area of research is the recent development of the 
CRISPR/Cas9 system for genome engineering, which couples a DNA double strand 
endonuclease to a short guide RNA to specifically target any site in the genome to 
disrupt, replace or modify the targeted gene
135,136
.   In the context of DMD, this gene-
editing approach induces exon deletion and reinstatement of dystrophin expression. 
Multiple studies have already shown efficacy in restoring dystrophin expression in 
myofibers, cardiomyocytes as well as satellite cells following both local and systemic 
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delivery using AAV
137–139
.  Due to this technology being very new, there is still a lot of 
research to be done in optimizing the system and evaluating long term therapeutic 
benefits. Off-target effects at other sites of the genome are also a genuine concern in 
human clinical application.  
 
Non gene-based therapies 
 
 Muscle augmentation via myostatin inhibition is another quickly advancing area. 
Myostatin is a transforming growth factor-β family member and a negative regulator of 
skeletal muscle mass. Inhibition of myostatin has been demonstrated to increase muscle 
mass in mdx mice
140–143
 and GRMD dogs
144
 and may be beneficial in DMD patients.  
A Phase I/II multicenter safety trial is currently being undertaken for MYO-029, a 
neutralizing antibody to myostatin
145
.  Another muscle augmentation approach involves 
enhancing insulin-like growth factor I (IGF-1) to enhance muscle regeneration and 
protein synthesis
146,147
.  A Phase I/II trial is currently assessing the impact of IGF-1 
treatment in preserving motor function in DMD patients.   
 Another strategy includes the use of stem cell therapy to regenerate muscle. This 
strategy is attractive as it requires only the use of stimulatory signals and/or small 
molecules to expand large numbers of cells. Induced pluripotent stem  cell  (iPSC) 
technology is one leading area of focus in stem cell therapy as it allows derivation of 
patient-specific pluripotent stem cell preparations. This obviates both ethical and 
immunological concerns that are associated with embryonic stems cells. One recent study 
showed proof-of-principle application of ex vivo genetic correction of dystrophic iPS 
cells with a micro-utrophin transgene before transplantation back into 
dystrophin/utrophin double knockout mice
148
. They observed that engrafted muscle had 
large numbers of corrected myofibers, restoration of the DGC complex, and improved 
contractile strength. Moreover, they observed seeding of the transplanted cells within the 
satellite cell compartment.  While these results are positive and exciting, this strategy still 
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has to overcome multiple important hurdles, such as improved survival of the cells post-
injection, effective migration to the compromised muscles, and successful engraftment. 
 An alternative strategy involves targeting of the membrane repair machinery. 
Recent advances have identified another component of the membrane repair process, the 
protein Mitsugumin 53 (MG53, also known as TRIM72). MG53 is a tripartite motif 
family protein (TRIM) found primarily in striated muscle, and its role is to facilitate 
vesicle trafficking during the process of membrane repair and nucleates the assembly of 
the repair machinery through a redox-dependent mechanism
93,95,149,150
. Injections of 
recombinant MG53 have been shown to mitigate pathology in mdx mice by increasing 
membrane repair in muscle fibers and prevent muscle injury in vivo
151
.   However, there 
are some concerns about the possible metabolic side effects of MG53 upregulation
152
. 
 Collectively, while there are no current clinically approved treatments for DMD, 
there are many potential avenues that can be undertaken to target the disease pathology 
and potential combinations of these strategies may end up being optimal in treating the 
disease. Unfortunately, none of these potential strategies to ultimately cure DMD are 
likely to be ready for clinical application in human patients in the near future, as most 
require optimization in methods, delivery, safety, as well as the process of having to go 
through lengthy clinical trials.  It is therefore crucial to find a therapeutic that can help 
improve and prolong quality of life in DMD patients. 
  
1.5.4 Consequences to tissue specific treatment  
 
 Current palliative care regimens and new promising therapeutic strategies are 
largely directed at aiding respiratory function and prevent/slow skeletal muscle 
degeneration but it is critical to consider the interplay between the skeletal and cardiac 
myopathies (Figure 2).  Leaving the skeletal myopathy untreated leads to blood flow 
adaptations and increased hemodynamic load on the heart while currently skeletal muscle 
centric therapeutic strategies for DMD also lead to increased stress on the untreated 
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myocardium presumably due to prolonged ambulation leading to increased cardiac 
demands
153
. A clear example is demonstrated in mice lacking both dystrophin and MyoD, 
a skeletal muscle specific key regulator of myofiber regeneration. Mice lacking 
dystrophin do not display cardiac abnormalities under baseline conditions but additional 
deletion of MyoD, which leads to impaired skeletal muscle regeneration and worsened 
skeletal phenotype, also induces severe cardiomyopathy
154
.  
 
Figure 2: Interplay between the skeletal and cardiac myopathies.   The optimal therapeutics 
will target all striated muscles simultaneously. 
 
This is further evidenced in X-linked dilated cardiomyopathy, an inherited 
disorder caused by mutations in dystrophin that induces either the loss of dystrophin or 
production of an aberrant dystrophin in the heart but does not affect skeletal muscles
12
 
and that affects some female carriers of Duchenne, and in Becker's muscular dystrophy 
patients, develop cardiomyopathy despite retaining healthy skeletal muscle function
155
. 
BMD patients with less affected skeletal muscle appear to have more severe decline in 
cardiac function
156
. Moreover, growing evidence from animal studies raise concerns over 
skeletal muscle centric therapeutics worsening the cardiac disease
153
. Mdx mice treated 
with a skeletal muscle specific mini-dystrophin transgene were observed to have 
significantly enhanced voluntary wheel running activity compared to non-transgene 
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treated mdx mice suggesting that enhanced exercise capability from skeletal muscle 
treatment provides a setting for increased cardiac workload and heightened stress
157,158
. In 
agreement, the transgene treated mdx cohort had significant increase in left ventricular 
diastolic volume and greater incidence of myocardial necrosis and intracellular 
immunoglobulin accumulation
159
. 
This highlights the significance of a novel therapeutic that can alleviate the whole 
disease by targeting both cardiac and skeletal muscle. Cardiac and skeletal muscles have 
important differences in both structure and function which need to be kept in 
consideration when developing therapies for DMD.  
 
 
1.6  Copolymer based membrane stabilizers for DMD  
 
Poloxamer 188 (P188), the lead membrane stabilizer molecule of interest, belongs 
to the class of synthetic block copolymer surfactants generally known as poloxamers or 
Pluronics, which are tri-block copolymers comprised of a hydrophobic polypropylene 
oxide (PPO) core block flanked on both sides by hydrophilic polyethylene oxide (PEO) 
chains (Figure 3) in a A-B-A architecture.  A wide range of copolymers with distinct 
physicochemical properties can be generated by varying the lengths of the PEO and PPO 
segments. 
 
Figure 3: Schematic representation of an A-B-A triblock copolymer.  Variation in PEOa 
(blue) and PPOb (red) block lengths leads to changes in physicochemical properties. 
 
Poloxamers were the first commercially produced block copolymers, synthesized 
by Wyandotte Chemical Corporation in the late 1940s for industrial purposes, and now 
widely found in both industrial and consumer products.  Poloxamers are mild, non-ionic 
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amphiphiles (having both hydrophilic and lipophilic properties) that exist at 10-80% wt. 
% poly(ethylene oxide) and 1-15000 g/mol molecular weights and have now been found 
to also have various biological applications such as drug delivery carriers, to enhance 
drug penetration in the treatment of multiple drug resistant tumors
160,161
, or membrane 
interacting agents, either as lysis detergents
162–164
 or cell membrane stabilizers
165,37,166
, the 
latter being directly attributed to poloxamers’ varying affinity for both the surrounding 
solvent and with the similarly amphiphilic phospholipid membranes
167–170
. The 
modulation of copolymer-phospholipid membrane interactions that results in therapeutic 
membrane stabilization in vivo is the major focus of this work. 
 
1.6.1 Poloxamer 188 
 
 The most commonly studied poloxamer is P188, with the earliest reported use in 
clinical research as a rheological agent in blood
171,172
.  P188 was used as a solubilizing 
agent of perfluorochemicals, which have significant O2 carrying capacity, to create an 
emulsion used as an artificial blood substitute
173
.  It was later determined that P188 
reduces endothelial adherence and improves the rheology of sickled red blood cells
174
, 
leading to P188 being pushed to clinical trial as a therapeutic agent for sickle cell 
anemia
175,176
. Its first FDA approved use in humans was as a skin wound cleanser due to 
its lack of toxicity to the cellular components of blood and its lack of interference to the 
wound's ability to heal and resist infection
177
. P188 was then first demonstrated to act as a 
cell membrane stabilizer when it was shown to reduce the electroporation-induced 
leakage of carboxyfluorescein dye from cells
165
.  P188 was also observed to reduce 
membrane fluidity and improve cell survivability during shear stress in HB-32 hybridoma 
cell lines, presumably through direct membrane interaction
53
 and has been widely 
deployed as a shear protective agent used in bioreactors
178
.  Of note, P188 has been 
demonstrated to significantly lower apparent membrane tension and restore membrane 
resealing cells treated with the tetanus toxin, which prevents exocytosis at sites of 
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membrane disruption and blocks membrane resealing
84
.   More recently, P188 has been 
reported to be protective against ischemic-reperfusion injury
179,180
, thermal
181
 and 
radiation burns
182,183
, myocardial infarctions
184–186
 and Duchenne muscular dystrophy 
cardiomyopathy
37,187,188
.  
 
1.6.2 Poloxamer 188 as a membrane stabilizer for DMD  
 
 Due to its membrane stabilizing capacity in various other membrane injury 
models, there has been strong interest in applying P188 to stabilize dystrophic muscle 
membranes. A first study has demonstrated that the acute application of P188 to isolated 
mdx cardiomyocytes restored myocyte compliance to wildtype levels while also reducing 
stretch-mediated calcium overload and preventing the intracellular uptake of the 
membrane probe FM1-43
37
.  Mdx cardiac myocytes demonstrate increased passive 
tension when load is applied which results from the influx of extracellular Ca
2+ 
and 
application of P188 completely normalizes passive compliance to normal levels.  At the 
level of the whole organ, P188 decreases passive tension and thereby improves 
myocardial relaxation allowing for complete filling of the ventricles and return to normal 
working end diastolic and end systolic volumes
12
. Moreover, in vivo administration of 
P188 to mdx mice improved ventricular geometry and prevented acute cardiac failure 
during a dobutamine stress protocol
37
.  Another study using the more diseased GRMD 
dog model demonstrated the effectiveness of chronic P188 administration at preventing 
left-ventricular remodeling, reducing myocardial fibrosis and blocking increased cardiac 
troponin I and brain type natriuretic peptide in the serum
187
. 
Another group has also demonstrated the effectiveness of chronic intermittent 
administration of P188 in protecting against beta-agonist isoproterenol induced 
cardiomyopathy in mdx mice
188
.  In comparison, the ability of synthetic membrane 
stabilizers to protect fragile DMD skeletal muscles has been less clear.  Early 
experiments with P188 have so far shown little to no efficacy in protecting dystrophic 
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limb skeletal muscle function in vivo
189,190
. However, P188 is effective in protecting 
hindlimb skeletal muscle in a range of other conditions, including electroporation 
injury
165,191
, hindlimb ischemia-reperfusion injury
180,192
, and in a model of dysferlin-
deficiency
193
.  
Furthermore, P188 has been demonstrated to confer protection to dystrophic 
skeletal muscle in vitro
194
. These examples raise the possibility that the ineffectiveness 
exhibited by P188 in dystrophic skeletal muscle in vivo in past work is due to sub-optimal 
pharmacodynamics of routes of delivery, with most in vivo work administering P188 via 
intravenous or intraperitoneal routes, rather than an intrinsic inability of P188 to 
beneficially stabilize dystrophic skeletal muscle.  
This hypothesis is supported by a study that found that intravenous infusion of 
P188 was protective against skeletal muscle electroporation injury in vivo in an animal 
model where impaired perfusion is not a factor
165,191
 . This notion is furthermore strongly 
supported by a recent study showing that chronic dosing of P188 using subcutaneous 
delivery improves diaphragm function in mdx and mdx:utr
-/-
 as well as improved both 
systolic and diastolic function in mdx hearts
195
. As the diaphragm is arguably one of the 
most affected skeletal muscles in DMD, these results are encouraging that similar 
protective effects could be observed in limb skeletal muscles via optimization of P188 
delivery.  
 
1.6.3    Pharmacokinetics of Poloxamer 188 
 
A distribution, metabolism and excretion study has been performed for purified 
P188 in rats, dogs, and healthy humans
196
.  P188 has been shown to be widely distributed 
throughout all organs following intravenous (IV) injections in various animal models 
with higher concentration in tissues with high blood flow, such as the heart
196,197
. P188 is 
primarily excreted by the kidneys without modification with a half-life of about 5 hours 
in small mammals and about 18 hours in humans
196,197
.  Adverse reactions including 
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muscle soreness, proteinuria and elevated liver enzymes have been reported following 
high concentrations perfusions of P188 in healthy human volunteers
198
. These have since 
been determined to be due to the presence of small molecular weight contaminants 
resulting from side reactions occurring during synthesis of the P188 batch used in the 
studies
199,200
.  Removal of these contaminants allowed high doses to be well tolerated in 
sickle cell patients
176
.  
To date, most safety and pharmacokinetic studies have been performed in order to 
examine acute intravenous P188 administrations in the context of phase I and II clinical 
trials for sickle cell anemia but there is a paucity of information on the pharmacokinetics 
of chronic P188 administration as well as little information on the pharmacodynamics of 
P188 following different delivery routes. It is also unclear if the pharmacokinetics and 
pharmacodynamics of P188 could differ in DMD. A small study performed in normal 
C56BL/6 mice comparing the plasma pharmacokinetics of a single low dose intravenous 
(4.6 mg/kg) or subcutaneous (3.0 mg/kg) dose revealed markedly different plasma level 
profiles, with plasma exposure to P188 greater in the subcutaneous dose than in the 
intravenous dose
195
.  These data indicate that the pharmacokinetics of P188 vary 
significantly depending on routes of delivery. 
  
1.6.4 Biophysical investigations of P188 - membrane interactions 
 
 Comprehending how P188 interacts with biological membranes is important to 
understand the basic mechanism of membrane stabilization by copolymers.  The 
interaction of P188 with membranes of various compositions has been the subject of 
numerous studies.  Systems using Langmuir troughs to modulate the surface area and 
therefore lipid packing density of supported phospholipid monolayers at the air/water 
interface have been used to model damage the outer leaflet of the lipid bilayer.  
 Langmuir isotherms and fluorescence microscopy have been used to analyze the 
ability of P188 and other poloxamers to interact with lipid membranes. Maskarinec et al. 
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focused on P188 insertion as a function of surface pressure, which directly correlates to 
lipid packing density, for both anionic dipalmitoylphosphatidylglycerol (DPPG) and 
zwitterionic dipalmitoylphosphatidylcholine (DPPC) monolayers and observed that P188 
inserts into both lipid types at a surface pressure (π) ≤  22 mN/m, which is lower than the 
equivalent surface pressure of a normal healthy cell membrane, and remains inserted until 
the surface pressure is increased back to a threshold surface pressure equivalent to that of 
a normal healthy membrane
201,202
.   
 X-ray reflectivity results show that at high surface pressure, lipid films with and 
without P188 exhibit similar electron density profiles
168,203
. This inability to remain 
inserted at this threshold surface pressure suggests that P188 may be naturally “squeezed 
out” from the cell bilayer once it has repaired itself. These results indicate that P188 will 
only adsorb onto localized areas of the membrane where the local lipid density is 
reduced. Moreover, similar results observed in DPPC and DPPG monolayers, which have 
different lipid head group charge, suggest that P188 interactions are not influenced by 
electrostatics. Morphologically, P188 insertion was found to tighten lipid packing via 
physical occupation of surface area
168,201
. P188 was found to rapidly "insert" into the 
membrane in a reversible manner, that is, P188 was promptly ejected out of the 
membrane once the surface pressure and lipid density were re-established back to 
normal
201,202
.   
 Based on these results, P188 therefore does not appear to interact with membranes 
when the phospholipid packing is normal. This led to the hypothesis that only when lipid 
packing density is low enough that the hydrophobic core of the monolayer is exposed that 
P188 partitions into the membrane via hydrophobic interactions. Moreover, P188 
partitions into the monolayer in localized patches rather than uniformly across the 
membrane
168
.  However, supported monolayers are a very simplistic approximation of 
biological bilayer membranes.  While artificial lipid monolayers are simple models to 
experimentally control and observe, the results obtained on those model systems cannot 
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be fully extended to biological membrane systems, which are structurally heterogeneous 
and complex.   
 Giant unilamellar vesicles (GUVs) with diameters of 10-50 um have been widely 
used as a three dimensional mimic of a cell bilayer due to their large size allowing for 
ease of observation with optical microscopy and ability to be loaded with components 
such as fluorescent dyes.  One study monitored the loss of structural integrity of single 
fluorescent dye-loaded GUVs undergoing a membrane swelling hypo-osmotic stress in 
the presence of 50 uM P188
169
.  GUVs undergoing hypo-osmotic stress show swelling 
and formation of transient pores through which leakage of fluorescent dye was 
monitored. The authors observed an incubation time-dependent two state mechanism to 
P188 interaction with the GUV: an adsorption state where P188 slows down GUV 
swelling and retards leakage of the intravesicular fluorescent dye, in time followed by an 
insertion state where very long incubation (~several days) leads to P188 inserting into the 
GUV membrane and induced lipid packing disruption and increased membrane 
permeability.  
 To more closely investigate the physical nature of P188-membrane interactions, 
1
H Overhauser dynamic nuclear polarization NMR spectroscopy was employed to closely 
examine the local hydration dynamics at the P188-lipid membrane interface
170
. The 
resolution permissible by this technique allowed for probing of the local water diffusivity 
in lipid bilayer systems and showed that P188's weak adsorption on the membrane 
surface was effective to retard membrane hydration dynamics and intrabilayer water 
diffusivity without transposing in the bilayer interior nor affective lipid packing
204
.       
 
1.6.5 Block copolymer structure-function 
 
Block copolymers are comprised of two or more distinct polymer moieties 
(blocks A,B,C…) covalently bonded together that exist in a variety of molecular sizes, 
relative degree of polymerization of each block  (composition), chemical moieties, and 
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architectures, from di-block (A-B), to tri-block (A-B-A, B-A-B, A-B-C…) to multi-
blocks (A-B-A-B-A) (Figure 4).  There are therefore almost infinite possible distinct 
chemical configurations of block copolymers that can be synthesized by varying the 
lengths of A and B segments, and not much is known on the structure-function 
relationships of these block copolymers in the context of both material and biological 
applications.  There is considerable interest on block copolymers due to their overall 
surface active and solvent-selective characteristics which are directly dictated by the 
specific blocks inherent thermodynamic properties
205,206
.  
 
Figure 4: Schematic drawing of two-component copolymers. Variation in PEO and PPO chain 
lengths leads to changes in physicochemical properties  
 
 Studies of the effects of poloxamers on lipid membranes showed that the 
hydrophobicity of the copolymer had a leading role in copolymer-membrane interactions, 
with more hydrophobic copolymers decreasing membrane microviscosity
164,207
, 
increasing the rate of lipids flip-flopping across the membrane outer and inner leaflets of 
vesicular membranes
164
, and increasing membrane leakiness
162,208
.  Studies have 
investigated whether the size of the hydrophobic PPO subunit regulates insertion 
capabilities of the copolymer into lipid films by testing poloxamers of 80% PEO 
composition but different molecular weights (P108, P238, P188 and P338) for their 
ability to insert with lipid monolayers
202
.  All were found to insert into lipid monolayers 
and while the copolymers with larger hydrophobic PPO subunits needed lower surface 
pressure for insertion, presumably due to the bulkiness of the hydrophobic core hindering 
their insertion compared to the copolymers with a smaller PPO core, they seemed to 
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maintain their positions more strongly once inserted, with P238 and P338 able to retain 
their positions at the monolayer at much higher surface pressures than the smaller P108 
and P188.  The length of the PPO subunit also influences the solubility of the copolymer 
in the lipid bilayer, with longer PPO subunits having stronger association constant.  
Moreover, copolymers with longer PPO subunits hinder lateral lipid diffusion more 
significantly than copolymers with shorter PPO subunits, indicating that longer PPO 
blocks allows for deeper insertion into the bilayer
209
. 
 Monte Carlo simulations run using a coarse-grained model to capture the main 
interactions between lipids and poloxamers show that changing poloxamer structure leads 
to differences in subphase solubility that is also reflected in the degree of lipid corralling, 
with more hydrophobic and therefore less soluble copolymers having higher adsorption at 
the membrane and causing lipid domains to be more ordered
167
.  Data presented from an 
isothermal titration calorimetry (ITC) study of poloxamer P338 interaction with 
liposomes confirm that lipid packing density indeed regulates how poloxamers associate 
with membranes, with poloxamers observed to not partition into ordered gel-phase 
bilayers but to partition with relative ease into fluid-phase disordered bilayers
210
.  
Moreover, results from that study show the existence of a saturation limit at which the 
lipid membrane can accommodate a maximum number of poloxamer molecules at a point 
beyond which the liposome integrity is disrupted. This observed outcome indicates that 
whether a poloxamer acts as a membrane stabilizer or a destabilizer depends in large part 
on the saturation limit of the membrane and poloxamer/lipid ratio.   
 Polyethylene glycol (PEO or PEG) is the hydrophilic constituent of poloxamers 
and has been well investigated in the fusion of model membranes and for its ability to 
lower water molecule activity at the membrane-solvent interface
211
. While PEG-mediated 
membrane stabilization has been shown to be effective, the millimolar to molar 
concentrations required for effectiveness compared to P188 indicate that a central 
hydrophobic component plays an essential role in driving P188 to effectively interact 
with and increase membrane stabilization potency
204
.     
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 Additionally, the incorporation of poloxamers into the lipid membrane was shown 
to be endothermic and therefore dominated by entropy, with a gain of entropy 
significantly contributing to the free energy of partitioning, due to the release of ordered 
water molecules surrounding the PPO chain upon its partitioning into the bilayer
169,170
. 
Furthermore, the favorable hydrophobic interactions between the PPO chains and the acyl 
chain of the lipid additionally contribute to the enthalpy-entropy balance.  Importantly, a 
poloxamer of equivalent PPO/PEO as P188 was found to predominantly incorporate into 
the outer leaflet of the liposome and only slowly migrated through the bilayer after 
incubation for an extended period of time
210
, indicating that there is a strong impediment 
to passive diffusion of copolymer across the cell membrane. This asymmetric distribution 
strongly suggests that it is energetically unfavorable for a poloxamer to adopt a bilayer 
spanning conformation. 
 In a study using GUVs undergoing hypo-osmotic stress in the presence of 
copolymers of varying hydrophobicity, incubation with the hydrophilic PEG, which is 
believed to only adsorb at the membrane interface, led to prolongation of the swelling 
process
169
, suggesting that the adsorption state of the copolymer is the membrane 
stabilizing state under hypo-osmotic conditions.  
 Further experiments examining other poloxamers of varying PPO subunit lengths 
indicate that the insertion rates of poloxamers correlates well with their 
hydrophobicity
164,167
. They concluded that while adsorption of poloxamers to the 
membrane interface is somewhat independent of architecture, insertion is however 
mainly dictated by their hydrophobicity
169
.  This was further confirmed by another study 
using isothermal calorimetry and small molecule directed lipid peroxidation of liposomes 
revealing that hydrophilic copolymers at uM concentrations such as P188 and PEG8000 
did not exhibit appreciable heat exchange indicative of insertion within their 
experimental time scale (4 hours) whereas hydrophobic poloxamers P335, P333 and P181 
displayed significant heat of partitioning indicative of insertion into the liposomal 
membrane
212
.  They hypothesized that the disruptive effect of copolymer insertion is due 
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to mismatch in size and hydrophobicity between the PPO block and the lipid hydrocarbon 
tails. This was further demonstrated in the increased instability of lipid-P188 mixed 
GUVs that was dependent on the concentration of P188 inserted at the membrane
169
.   
 These findings underlie the hydrophobicity dependence of differential kinetics of 
insertion between poloxamers, with more hydrophobic copolymers inserting at faster 
rates by initially embedding below the lipid head group region, opening up the packing of 
acyl chains, and accelerating the passage of molecules such as water across the 
membrane
170,204
.      
 
1.6.6  Micellization/Aggregation behavior of block copolymers 
 
 One parameter of biological importance is the critical micelle concentration 
(CMC), which is defined as the isothermal copolymer concentration at which micelles of 
an amphiphilic copolymer start to self-assemble and at which equilibrium between 
unimeric copolymers and micelles is established
213,214
. The main driving force for self-
assembly is the solubility differences between blocks. Also, while not a linear rule, as 
molecular size and specifically, the size of the hydrophobic chain increases, the free 
energy to keep the molecule solvated increases, and CMC therefore decreases.  
 Temperature also plays a crucial role in micelle formation with CMC of block 
copolymers tending to decrease with rising temperature
178
.  This phenomenon is at least 
in part attributed to the dehydration of PEO blocks at higher temperature and 
consequently a lower solubility of the PEO chains in water. A list of reported CMCs for 
P188 and other poloxamers are presented in Table 1.  Experimental determination of 
CMC can be conducted using various techniques where a break in the curve of a 
measured signal against concentration signifies the start of micellization
178,215–217
.   
 The most common methods of CMC determinations are surface tension 
measurements, scattering, viscosity, and fluorescent dye solubilization. The latter is the 
most widely used, typically involving measuring the emission or absorbance of insoluble 
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fluorescent probes such as DPH or pyrene that fluoresce when solubilized in 
micelles
178,218
. There is however significantly variable sensitivity and accuracy across 
methods complicated by the fact that micellization of block copolymers is significantly 
more complex than for small molecules species.   
 
Reported 
CMC (mM) 
Temperature 
(C˚) 
Reference 
1.4 25 
219
 
0.125 30 
201
 
0.5 37 
220
 
5 37 
221
 
8.3 40 
178
 
 
Table 1:  Reported CMCs for P188 using various detection methods. 
 Nevertheless, CMC is a critical parameter to consider when thinking about 
biological applications. The behavior of the monolayer differed above and below the 
CMC of P188, suggesting the unimeric form of the block copolymer is suggested to be 
the active agent.  While it remains unclear whether or not in vivo micellization would 
occur at certain concentrations and how that would affect in vivo pharmacokinetics and 
pharmacodynamics once injected, it is important to keep in mind the potential 
physiological implications of poloxamer self-aggregation and dissociation.  
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1.7  Thesis overview and major objectives 
 
1.7.1 Membrane-stabilizing copolymer efficacy in dystrophic skeletal muscle 
 
 The principal objective of Chapter 2 was to assess copolymer P188 efficacy in 
preserving dystrophic skeletal muscle function and sarcolemmal integrity in vivo.  
Despite wide usage of P188 in pre-clinical studies to stabilize membranes from various 
injury modalities, it is surprising that basic elements of P188 pharmacodynamics have not 
been examined in the context of DMD skeletal muscle. It is well established that drugs 
and molecules exhibit a wide range of pharmacokinetic and pharmacodynamics 
properties in vivo depending on covariants such as size of the drug or molecule, its 
chemical composition, and importantly, the route of delivery
222,223
. Thus, the 
pharmacodynamics of P188 was investigated by directly comparing the functional effects 
between three parenteral delivery routes: intravenous, subcutaneous and intraperitoneal.  
A hindlimb skeletal muscle lengthening contraction protocol was employed as a well-
established quantitative measure of the consequences of dystrophin-deficiency in 
vivo
36,46,102,224,225
 to test whether P188 can prevent the force loss and membrane instability 
associated with lengthening contractions in mdx mice.  Results indicate that 
pharmacodynamics optimization of P188 delivery is critical to conferring protection 
against force loss to dystrophic skeletal muscle undergoing physiological stress. 
Moreover, another triblock copolymer of equivalent composition as P188 but larger size 
also demonstrates membrane stabilization in vitro and in vivo.  These findings establish 
proof-of-principle that support synthetic membrane stabilizers as a first-in-class 
therapeutic strategy for prevention of injury in dystrophic skeletal muscle in vivo. 
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1.7.2  Structure-function relationship of membrane stabilizing diblock copolymers 
 
 The principal objective of this aim was to seek a deeper understanding of block 
copolymer structure-function to provide insights into the membrane stabilizer mechanism 
of action. It is currently unclear how the structural properties of P188 confer its 
membrane stabilizing functionality.  Biophysical studies investigating the mechanism of 
interaction for P188 and other poloxamer formulations with phospholipid monolayers 
suggest that the PPO/PEO ratio is a critical variable for membrane interaction
169,202,212
.  
Investigations up to now have focused on the triblock architecture of the poloxamer 
family, which are constrained to those that have been synthesized and made 
commercially available by the chemical company BASF. For a more effective structure-
function approach, it is necessary to explore the role of architecture i.e., whether a 
triblock architecture is necessary for membrane stabilization.  To do so, the diblock 
architecture (A-B) is explored in Chapter 3.  Diblocks are an attractive alternative option 
to triblocks because they have a simpler synthetic process which allows for methodical 
alterations to PPO/PEO and block lengths.  Furthermore, removal of one of the PEO 
chains allows for customization of the PPO block functional end group with different 
chemical moieties to strategically and more minutely modulate block hydrophobicity in 
order to fine tune copolymer-bilayer interactions. Results from the work in this chapter 
are the first to establish the efficacy of the diblock architecture for membrane 
stabilization. Moreover, as exciting proof-of-principle, addition of a small hydrophobic 
end group to the PPO block significantly enhances membrane protection in vivo, leading 
to an “anchor and chain” hypothesis of bilayer interaction. The ability to more easily 
customize diblock chemical properties eases access to a vast chemical landscape to be 
further explored. 
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1.7.3 Atomistic level investigation of block copolymers interaction with  lipid 
 membranes using Molecular Dynamics simulations 
  
Despite previous investigations on poloxamers, and specifically their   
interactions with lipid membranes, it remains unclear what is the mechanism of 
interaction and the driving force behind these interactions.  In this regard, molecular 
dynamics (MD) simulations have been well established as a method of choice to probe 
both location and dynamics of membrane active molecules that cannot easily be observed 
with experimental techniques. As of today, there are few reports detailing MD 
simulations to study poloxamer-membrane interactions
167,208,226,227
 and most use a 
computationally less intensive and partial model that lack atomistic level insight.  
The principal objective of Chapter 4 of this work was to use all-atomistic MD 
simulations to provide molecular insight on the effect of lipid bilayer surface tension 
changes on P188-bilayer interactions. Increases in surface tension applied to the lipid 
bilayer revealed an area-per-lipid dependence of adsorption vs. insertion of P188, which 
supports monolayer studies that demonstrated that P188 inserts into areas of decreased 
lipid density and gets “squeezed-out” once membrane integrity is restored202.  Another 
new finding that resulted from this study is the observation that one or both PEO chains 
of the triblock initiate insertion of the copolymer, hypothetically as a priming step to 
lower solvent accessible area on the hydrophobic PPO block.  
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2.1  Summary  
 
 Duchenne muscular dystrophy (DMD) is a fatal disease of striated muscle 
deterioration. A unique therapeutic approach for DMD is the use of synthetic membrane 
stabilizers to protect the fragile dystrophic sarcolemma against contraction-induced 
mechanical stress. Block copolymer-based membrane stabilizer poloxamer 188 (P188) 
has been shown to protect the dystrophic myocardium.  In comparison, the ability of 
synthetic membrane stabilizers to protect fragile DMD skeletal muscles has been less 
clear.  Because cardiac and skeletal muscles have distinct structural and functional 
features, including differences in the mechanism of activation, variance in sarcolemma 
phospholipid composition, and differences in the magnitude and types of forces 
generated, we speculated that optimized membrane stabilization could be inherently 
different.  Our objective here is to use principles of pharmacodynamics to evaluate 
membrane stabilization therapy for DMD skeletal muscles. Results show a dramatic 
differential effect of membrane stabilization by optimization of pharmacodynamic-guided 
route of poloxamer delivery.  Data show that subcutaneous P188 delivery, but not 
intravascular or intraperitoneal routes, conferred significant protection to dystrophic limb 
skeletal muscles undergoing mechanical stress in vivo. In addition, structure-function 
examination of synthetic membrane stabilizers further underscores the importance of 
copolymer composition, molecular weight, and dosage in optimization of poloxamer 
pharmacodynamics in vivo. 
 
 
2.2  Introduction 
 
 Duchenne muscular dystrophy (DMD) is an X-linked recessive disease of marked 
striated muscle deterioration affecting 1 in 3500-5000 boys
10
.  DMD results from the lack 
of the cytoskeletal protein dystrophin, which is essential for maintaining the structural 
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integrity of the muscle cell membrane
1
. DMD patients develop severe skeletal muscle 
degeneration, along with clinically significant cardiomyopathy
19,228,229
.  There is no cure 
for DMD patients, or any effective treatment to halt, prevent or reverse DMD striated 
muscle deterioration.  Symptomatic clinical management includes glucocorticoids that 
show positive improvements in muscle strength and cardiac function
98,104
 but also have 
significant negative side effects
101,103
.  Current experimental DMD therapeutics are novel 
gene and cell-based strategies,
230,231
 including exon-skipping strategies to restore 
dystrophin production which have shown some promise in pre-clinical studies
124,126,127,232
.  
To date, however, these approaches have not yet been translated successfully in human 
patients
129,130
.  In this context, it is essential to consider additional approaches that target 
the primary defect of DMD: severe muscle membrane fragility. 
 DMD is a particularly daunting disease because striated muscle represents ~40% 
of body mass, and includes all skeletal, respiratory and cardiac muscles.  This point is 
important, as leading experimental therapeutic efforts to date appear to preferentially 
target dystrophic skeletal muscles, leaving the diseased heart untreated
12
. Skeletal 
muscle-centric strategies to improve ambulation for DMD patients could lead to 
increased stress on the untreated dystrophic myocardium as a result of increased cardiac 
demands
12,153
. This interplay between the progression of DMD cardiomyopathy and the 
skeletal myopathy as a pathophysiological load on the heart underscores the importance 
of a therapeutic strategy that can simultaneously treat all striated muscles. 
 The primary pathophysiological defect in DMD is the marked susceptibility to 
contraction-induced membrane stress
34,233
 and the subsequent muscle damage and 
degeneration that occurs due to loss of muscle membrane barrier function.  In this 
context, a unique therapeutic approach is the use of synthetic membrane stabilizers.  This 
strategy aims to prevent muscle degeneration by directly stabilizing the dystrophin-
deficient sarcolemma during muscle contraction.  The triblock copolymer poloxamer 188 
(P188) has numerous features that make it an attractive synthetic membrane stabilizer 
candidate for DMD treatment.  P188 (8.4 kDa) is a nonionic block copolymer belonging 
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to a family of triblock copolymers comprised of a hydrophobic polypropylene oxide 
(PPO) core flanked on either side by hydrophilic chains of polyethylene oxide (PEO) 
(Table 1).  We and others have shown that both acute and chronic delivery of membrane 
stabilizer P188 confers protection to the dystrophic myocardium and in both small and 
large animal models of DMD
37,187,195,234
. However, P188 has so far shown little to no 
efficacy in protecting dystrophic limb skeletal muscle function in vivo
187,189,190
.  This 
apparent non-efficacious effect is interesting considering that P188 is effective in 
protecting hindlimb skeletal muscle in a range of other conditions, including 
electroporation injury
165
, hindlimb ischemia-reperfusion injury
180
, and in a model of 
dysferlin-deficiency
193
 in vivo. Furthermore, P188 does confer protection to dystrophic 
skeletal muscle in vitro
194
.  These examples raise the possibility that the ineffective 
protection exhibited by P188 in dystrophic skeletal muscle in vivo in past work
189
 is due 
to sub-optimal pharmacodynamics, rather than an intrinsic inability of P188 to 
beneficially stabilize dystrophic skeletal muscle. We therefore hypothesize that 
optimization of pharmacodynamics of P188 is crucial in conferring protective efficacy to 
dystrophic skeletal muscle in vivo.   
 
 
Polymer 
 
Pluronic® 
 
Average MW (Da) 
 
2(PEOa) 
 
PPOb 
 
PPO/PEO 
P188 F68 8400 160 27 0.17 
Ext-P188 F108 14600 280 44 0.16 
P331 L101 3800 14 54 3.86 
PEG8000 - 8000 - - - 
 
Table 1: Summary of triblock copolymers. Pluronic®: BASF trademark designation; PEO: 
Polyethylene oxide; PPO: Polypropylene oxide; HLB: hydrophile-lipophile balance where a high 
HLB value indicates a relatively more hydrophilic polymer. 
 
 The objective of this study was three-fold. First, we tested whether block 
copolymers can stabilize dystrophic skeletal muscle membranes in vitro, thereby 
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bypassing any potential in vivo pharmacodynamic/kinetic barrier to the molecule. 
Second, we sought a deeper understanding of block copolymer P188 structure-function to 
provide insights into the membrane stabilizer mechanism of action. P188 belongs to a 
family of block copolymers called Poloxamers (or Pluronics) that are available in varying 
molecular weights and PPO/PEO (hydrophobic/ hydrophilic) ratios.  It is currently 
unclear how the structural properties of P188 confer its membrane stabilizing 
functionality.  Biophysical studies investigating the mechanism of interaction for P188 
and other poloxamer formulations with phospholipid monolayers suggest that the 
PPO/PEO ratio is a critical variable for membrane interaction
169,202,212
.  Accordingly, we 
investigated triblock copolymer composition and mass to gain insight into the role of 
these structural features on skeletal muscle membrane stabilization function in vitro.   
 The third and principal objective of this work was to assess copolymer P188 
efficacy in preserving dystrophic skeletal muscle function and sarcolemmal integrity in 
vivo.  Despite wide usage of P188 in pre-clinical studies to stabilize membranes from 
various injury modalities, it is surprising that basic elements of P188 pharmacodynamics 
have not been examined in the context of DMD skeletal muscle models in vivo. It is well 
established that drugs and molecules exhibit a wide range of bioavailability and 
pharmacokinetic/pharmacodynamic properties in vivo depending on covariants such as 
size of the drug or molecule, its chemical composition, and importantly, the route of 
delivery
222,223
. Thus, we investigated the pharmacodynamics of P188 by directly 
comparing the in vivo functional effects between three parenteral delivery routes: 
intravenous, subcutaneous and intraperitoneal.  We employed a hindlimb skeletal muscle 
lengthening contraction protocol as a well-established quantitative measure of the 
consequences of dystrophin-deficiency in vivo
36,46,102,224,225
. We tested whether P188 can 
prevent the force loss and membrane instability associated with lengthening contractions 
in mdx mice, the mouse model of DMD.  Results indicate that pharmacodynamic 
optimization of P188 delivery is critical to conferring protection against force loss to 
dystrophic skeletal muscle undergoing physiological stress. These new findings support 
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synthetic membrane stabilizers as a first-in-class therapeutic strategy for prevention of 
injury in dystrophic skeletal muscle in vivo. 
 
 
2.3  Results  
 
Membrane stabilization prevents membrane stress-induced leakage of LDH from 
dystrophin-deficient skeletal muscle cells in vitro 
 
 We used a hypo-osmotic stress as a structure-function screening tool to assess 
membrane stabilizer effects on skeletal muscle cells in vitro
235,236
.  Hypo-osmotic stress 
involves sarcolemmal swelling and stretching and can serve as an in vitro mechanical 
stress model. We used this model to evaluate the membrane stabilizing capacity of P188 
by its ability to prevent the release of an intracellular enzyme, lactate dehydrogenase 
(LDH), from normal and dystrophic muscle cells. Because myotubes derived from 
satellite cells can be grown to high density and maintained in culture more efficiently 
than isolated myofibers, we used control (dystrophin and utrophin replete) myotubes 
derived from an ex vivo expansion of satellite cells using conditional expression of Pax3 
as an initial test bed for membrane stabilization screening. Furthermore, in order to 
examine the structure-function relationship between the PPO/PEO ratio, molecular 
weight, and membrane stabilization, we examined the LDH release blocking efficacy of 
several other triblock copolymers (Figure 1A, Table 1).   
 In control satellite cell-derived myotubes exposed to hypo-osmotic stress, P188 
treatment decreased LDH release in a dose-dependent manner (~20% decrease in LDH 
release at 1 µM and ~50% decrease at 150 µM, 
#
P = 0.017) (Figure 1B).  Moreover, 
extended-P188 (ext-P188), a triblock copolymer featuring an equivalent PPO/PEO ratio 
to P188 at a larger molecular weight, was as effective as P188 at lower concentrations 
(~70% decrease in LDH release at 1 µM),  suggesting that membrane stabilization 
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capacity in vitro is linked to molecular size and that the original P188 characteristics can 
be optimized for increased potency.  In contrast, the completely PEO based PEG8000 
decreased LDH release to a much lesser extent than P188 (~35% decrease in LDH release 
at 150 µM), indicating that a hydrophobic component is required for optimal block 
copolymer-based membrane stabilization.  Because the addition of copolymers at µM 
concentrations did not affect total solution osmolarity (data not shown), membrane 
stabilizing effects can be attributed to direct stabilization at the membrane rather than 
osmotic factors. Conversely, the small and highly hydrophobic block copolymer P331 
(Table 1) induced lysis of the myotubes and exacerbated the release of intracellular LDH, 
indicating that highly hydrophobic polymers destabilize membranes, which is in 
agreement with previous reports
169,170
.   
 We next examined whether the membrane stabilizers P188 and ext-P188 were 
also effective in protecting dystrophic skeletal muscle membranes. To do so, we used 
isolated FDB (Flexor Digitorum Brevis) myofibers from mdx mice, as well as iPSC-
derived skeletal myotubes from mdx:utrn
-/- 
mice as they provide an in vitro model where 
both dystrophin and its compensatory homolog utrophin are absent, making it a closer 
functional mimic to DMD. The iPSC-derived model was used for procuring mdx:utrn
-/- 
 
myotubes as isolation of myofibers from these mice is technically challenging. Acutely 
isolated single FDB fibers from mdx mice, and iPSC-derived myotubes from mdx:utrn
-/- 
mice were thus subjected to hypo-osmotic stress and assessed for LDH release (Figure 
2A,B). P188 (150 µM) significantly decreased the release of LDH (~65% decrease 
compared to non-treated,*P < 0.05). Moreover, ext-P188 was again highly protective at a 
lower dosage, with 1 µM ext-P188 showing a similar extent of protection as 150 µM 
P188 (P = 0.49) and protection extending even to a lower 0.1 µM concentration.  
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Figure 1: In vitro hypo-osmotic stress assay to screen block copolymers for membrane 
stabilization. (A) Schematic representation of the tested triblock copolymers and the exclusively 
PEO-based polymer PEG8000, showing relative PPO (red) and PEO composition (blue).  (B) 
Satellite cell-derived myotubes from normal muscle were exposed to hypo-osmotic stress media 
and lactate dehydrogenase (LDH) enzyme release into the media was measured as a marker of 
membrane breach. The ability of P188 and other copolymers to decrease LDH leakage from 
stressed myotubes was assessed as a parameter of membrane stabilization. Data are presented as 
% LDH release normalized to total LDH release (*P < 0.05, via one-way ANOVA compared to 
non-treated group, 
#
P < 0.05 indicates 150 µM P188 is significantly different from 1 µM P188, 
&
P < 0.05 indicates 1 µM ext-P188 is significantly different from 0.1 µM ext-P188). Mean values 
are derived from at least 3 independent experiments with 3-4 wells of densely cultured myotubes 
per experiment. Error bars shown as mean +/- S.E.M. 
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Figure 2: Membrane stabilizers P188 and ext-P188 decrease hypo-osmotic stress-induced 
release of LDH in dystrophic myotubes and myofibers in vitro.  (A) Isolated mdx Flexor 
Digitorum Brevis (FDB) myofibers and (B) double knockout (dys/utr 
-/-
) myotubes were 
subjected to hypo-osmotic stress and lactate dehydrogenase (LDH) release was assessed in the 
absence (non treated) or presence of increasing concentrations of P188 and ext-P188. Data 
presented as % LDH release normalized to total LDH release from non-treated. *P < 0.05 via 
one-way ANOVA compared to non-treated group. Mean values are derived from at least 3 
independent experiments with 3-4 wells of 20-30 isolated mdx FDB myofibers or densely 
cultured dys/utr 
-/-
 myotubes per experiment. Error bars shown as mean +/- S.E.M. 
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Membrane stabilization markedly protects against lengthening contraction-
induced force loss and membrane instability in mdx skeletal muscles in vivo.  
 
 The mdx mouse exhibits significant susceptibility to lengthening contraction 
injury, as evidenced by a marked force loss after successive lengthening 
contractions
34,224
. Lengthening contraction injury protocols have been well used as an 
outstanding preclinical assessment assay for evaluating potential therapeutic strategies in 
mdx mice
102,115,116,123,232,237–239
. Force loss during contraction-induced muscle injury is a 
definitive quantitative functional marker of the disease in animal studies, making it a 
gold-standard physiological benchmark. We therefore evaluated the impact of P188 
treatment on in vivo physiological function of the hindlimb anterior crural muscle group 
(dorsiflexors) of mdx mice undergoing a lengthening injury protocol.  The in vivo 
hindlimb assay is informative as it allows for a maximal, reproducible, and non-invasive 
torque measurement of the entire anterior crural muscle compartment (including the TA 
and EDL muscles) via stimulation of the common peroneal nerve, and has been utilized 
by us and others to assess the efficacy of treatment modalities in the skeletal muscles of 
dystrophic mice 
66,239–242
.  Specifically, we investigated whether different parenteral 
routes of drug delivery (intraperitoneal, intravenous and subcutaneous) could lead to 
P188 efficacy in vivo. First-in-class membrane stabilizer P188 was evaluated at a dosage 
(460 mg/kg) that was previously shown to be effective in protecting the mdx heart in vivo 
as well as in mitigating electropermeabilization damage in rat skeletal muscle
165,37
. 
Lengthening contraction-induced force loss was markedly higher in mdx mice compared 
to C57/BL10 mice, with most of the force loss in mdx mice occurring within the first 15 
contractions (Figure 3).  Intraperitoneal (IP) and intravenous (IV) delivery of P188 
showed no significant effect on muscle function (Figure 3A, B), nor improvement in 
post-injury isometric force (Figure 6A, B).  
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Figure 3: Intraperitoneal and intravenous delivery of P188 have no effect to protect against 
lengthening contraction-induced force loss in mdx mice in vivo.  Force loss by the anterior 
crural muscles in adult mdx mice (n = 5-8 per group) treated with 460 mg/kg P188 or saline 
vehicle either (A) intraperitoneally (IP) or (B) intravenously (IV), at least 30 min before the 
injury protocol was assessed over the course of 50 lengthening contractions. Force loss is 
presented as a fraction of the initial maximal force +/- S.E.M. Contractions #1-15 show the 
marked force deficit in mdx mice. Results from BL/10 control mice injected saline via each 
delivery route are also shown. Inset (A,B) shows all 50 contractions. Both IP and IV delivery of 
P188 had no significant effect to decrease force loss over the course of the protocol. Error bars 
shown as mean +/- S.E.M.  
 
In marked contrast, subcutaneous (subQ) delivery of P188 led to dramatic 
improvement in mdx hindlimb muscle function. Here, force loss was not statistically 
different from C57BL/10 over 25 lengthening contractions (P > 0.10), and resulted in 
significantly higher force production than saline treated mdx mice over the entire injury 
protocol (*P < 0.05 for contractions #5-50 vs. mdx subQ saline) (Figure 4).  P188 
treatment also significantly decreased baseline and lengthening contraction-induced 
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increased Evans Blue dye uptake in mdx TA muscle (Figure 5). Additionally, post-injury 
isometric force in the subQ P188 treated group was significantly higher than saline 
treated mdx (*P < 0.05), and not significantly different from the C57BL/10 saline group 
(P = 0.45) (Figure 6C). In contrast, subQ delivery of a PEO homopolymer of similar 
molecular weight (PEG8000, 8 kDa) showed no improvement in muscle function 
(Supplemental Figure 1).          
 
 
Figure 4: Subcutaneous delivery of P188 markedly protects against lengthening 
contraction-induced force loss in mdx mice in vivo.  (A) Representative individual force 
tracings during lengthening contractions #1 vs #10 for subQ saline and subQ P188 treated mdx 
mice.  (B) SubQ P188 delivery confers significant protection against force loss from contractions 
#5-50 (*P < 0.05 via two-way ANOVA compared to the mdx saline group. Contractions #1-15 
are highlighted with the entire protocol shown in inset. Error bars shown as mean +/- S.E.M (in 
some cases symbol size was larger than error bar). 
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Figure 5: P188 significantly decreases baseline and lengthening contraction-induced 
sarcolemmal instability.  (A) Example images of Evans Blue dye uptake into TA myofibers 2 h 
post injury in mdx mice treated subQ with saline or P188.  (B) Quantification of total Evans Blue 
Dye extracted from whole TA muscles. Evans Blue dye was extracted by incubating the whole 
TA muscle in 1 mL of formamide.  "C" denotes the contralateral non-injured TA, "LC" denotes 
lengthening contraction.  Data is shown as absorbance at 620 nm divided by mg of tissue. **P < 
0.01, ***P < 0.001 via one-way ANOVA.  Error bars shown as mean +/- S.E.M.   
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Figure 6:  Isometric force measurements in P188 treated mdx mice immediately post-injury.  
IP (A) and IV (B) P188 delivery had no significant effect on peak isometric force immediately 
after injury whereas subQ P188 treatment (C) significantly enhanced immediate post-injury 
isometric force compared to mdx saline, and was not significantly different from BL/10 saline 
group.  *P < 0.05 one-way ANOVA compared to mdx saline, 
#
P < 0.05 one-way ANOVA 
compared to BL/10 saline. Error bars shown as mean +/- S.E.M. 
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 The in vitro results showed that ext-P188, a block copolymer of identical 
PPO/PEO ratio but of increased molecular weight than P188, can also stabilize 
dystrophic skeletal muscle membranes (Figure 2A, B).  To further the structure-function 
understanding of how block copolymer size and PPO/PEO ratio affects in vivo efficacy 
and pharmacodynamics, we next examined whether ext-P188 could confer protection 
from lengthening contraction-induced force loss. Because ext-P188 showed efficacy at 
low µM concentrations in vitro, we tested ext-P188 at low (60 mg/kg) and high (160 
mg/kg) dosages. Interestingly, and in contrast to P188, ext-P188 delivered IP at the low 
dosage significantly decreased force loss in mdx mice undergoing the lengthening injury 
protocol (*P < 0.05 for contractions #8-50) (Figure 7A). The post-injury isometric force 
loss was also not different from the C57/BL10 saline group (P = 0.42) (Figure 8). This 
protective effect was not observed with either IV or subQ delivery and was lost at the 
high dosage (Figure 7B, C and Figure 8).  Because a lower volume of the stock ext-
P188 was needed to achieve a 60 mg/kg dose, we also tested whether intramuscular (IM) 
delivery directly into the TA muscle would optimize its pharmacodynamics. Similarly to 
the IP injection, IM injection of ext-P188 significantly decreased force loss during the 
lengthening injury protocol (Figure 7D) (*P < 0.05 for contractions #6-50) and isometric 
peak force recovery was comparable to control mice given saline IM (P = 0.86).  These 
results indicate that a larger triblock copolymer of equivalent PPO/PEO ratio to P188 is 
capable of conferring protection to dystrophic skeletal muscle during physiological stress 
and that molecule size, dosage and route of delivery are all critical parameters for optimal 
pharmacodynamics.   
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Figure 7: Dose and delivery route dependence of ext-P188 in protecting mdx mice skeletal 
muscle from lengthening contraction-induced force loss in vivo. Mdx mice were administered 
either low dose (60 mg/kg) or high dose (160 mg/kg) ext-P188 via intraperitoneal (A) (IP), (B) 
intravenous (IV)) or (C) subcutaneous (subQ) injection at least 30 minutes prior to the protocol 
and the anterior crural muscle group tested for lengthening contraction-induced force loss over 
the course of 50 contractions. Force loss is presented as a fraction of the initial maximal force +/- 
S.E.M. Contractions #1-15 are graphically emphasized. (A) High dose ext-P188 (160 mg/kg) had 
no protective effect against lengthening contraction-induced force loss. However, low dose ext-
P188 (60 mg/kg) significantly improved resistance to injury from contraction #8 through #50 (*P 
< 0.05 via two-way ANOVA compared to mdx saline).  (B-C) Neither low dose nor high dose 
ext-P188 administered IV or subQ had any significant effects on force deficit.  (D) Low dosage 
60 mg/kg ext-P188 was injected into the Tibialis Anterior (TA) muscle of mdx mice directly prior 
to the protocol. Ext-P188 treated mice had a highly significant and sustained resistance to 
lengthening contraction injury loss (contractions 6-50, *P < 0.05 two-way ANOVA compared to 
mdx saline). Contractions #1-15 are graphically emphasized, entire protocol shown in inset.  Error 
bars shown as mean +/- S.E.M (in some cases symbol size was larger than error bar). 
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Figure 8:  Isometric force measurements in ext-P188 treated mdx immediately post-injury.  
(A) Low dose (60 mg/kg) ext-P188 delivered IP significantly prevented post lengthening protocol 
isometric force loss (*P < 0.05 one-way ANOVA compared to mdx saline) although was 
significantly different from the BL/10 saline group loss (
#
P < 0.05 one-way ANOVA compared to 
BL/10 saline). (B-C) No significant effect obtained for IV or subQ ext-P188 treated mice. (D) 
Post-injury isometric force of mdx mice treated with direct injection of 60 mg/kg ext-P188 into 
the TA muscle was not significantly different from BL/10 saline (
#
P = 0.74, one-way ANOVA 
compared to BL/10 saline). Error bars shown as mean +/- S.E.M. 
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Supplementary Figure S1: Hydrophilic PEG8000 does not protect against force loss in vivo. 
Adult mdx mice with either with saline vehicle or 460 mg/kg PEG8000 subcutaneously (subQ) at 
least 30 min prior to the injury protocol were assessed for anterior crural muscle force loss over 
the course of 50 lengthening contractions (A) and for immediately post injury isometric force 
assessment (B). PEG8000 had no significant effect on the force loss. Force loss is presented as a 
fraction of the initial maximal force +/- S.E.M. 
 
 
2.4  Discussion  
 
 Our results provide the first evidence, to our knowledge, that synthetic membrane 
stabilizers significantly protect dystrophic limb skeletal muscles during physiologically 
relevant mechanical stress in vivo.  A striking feature of this protective effect is that it is 
critically dependent upon route of delivery.  We report that pretreatment of mdx mice 
with subcutaneous injection of P188 confers marked protection from lengthening 
contraction-induced force loss in vivo.  The degree of protection from repetitive 
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lengthening contractions enabled mdx skeletal muscle to function similarly to control 
C57Bl/10 mice, with the protection achieved being comparable to transgenic animal 
studies using highly functional dystrophin molecules
115,118,123,128
.   In contrast, two other 
widely used parenteral means of drug delivery, intraperitoneal and intravenous, showed 
no beneficial effects. This is direct evidence that the lack of skeletal muscle efficacy 
reported in previous studies using P188
189,190
 can be attributed to suboptimal mode of 
delivery of P188, rather than a fundamental limitation in the mechanism by which the 
block copolymer stabilizes fragile skeletal muscle membranes.  These new findings 
underscore the importance of  pharmacodynamic optimization, which is essential for 
drugs to reach clinical efficacy
222,223
.  These findings, taken together with previous 
findings in dystrophic myocardium
37,187,234
 along with a recent study demonstrating the 
efficacy of chronic delivery of P188 in improving both cardiac and respiratory function in 
dystrophin-deficient mice
195
,  are evidence that synthetic membrane stabilizers provide a 
unique first-in-class drug strategy for treating all affected striated muscles in DMD.  The 
use of block copolymer-based membrane stabilizers as systemically delivered functional 
surrogates for dystrophin is further attractive, in that the mechanism of action is not 
limited by the specific DMD genetic lesion.  Thus, in principle, synthetic membrane 
stabilizers could be applicable to all DMD patients, regardless of genetic mutation.   
 Pharmacodynamics is defined as the functional effects of a drug on the body, and 
incorporates optimization of route of delivery
222,243
.  To date, no other study has tested 
P188 pharmacodynamics in the context of dystrophic skeletal muscle disease. It is well 
established that delivery route significantly affects pharmacodynamics and bioavailability 
of molecules injected into the body
222,243
.  Differential effects of delivery could serve to 
explain why previous studies using intraperitoneal injections showed no efficacy of P188 
to prevent mdx mice skeletal muscle injury in vivo
189,190
.    Pharmacokinetics (PK) of 
P188 (the effects of the body on the disposition of P188 once it is injected) have recently 
been reported in mdx mice.  Blood concentrations and clearance of P188 were assessed 
comparing IV and subQ routes of P188 administration in mdx mice and  results showed 
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enhanced plasma exposure over time via subQ administration compared to IV dosing
195
.  
These findings of differential pharmacodynamics based on route of P188 delivery may 
help explain the skeletal muscle protection we found by subQ but not IV administration. 
The marked differences in protective effects observed between the parenteral 
delivery routes suggest a differential systemic distribution of P188 to the hindlimb 
muscle tissues. It is widely supported that subcutaneous delivery leads to the slowest rate 
of absorption among the parenteral routes of delivery, which may come as a result of a 
subcutaneous drug depot promoting a sustained release effect
244,245
.  Although 
intraperitoneal injection is the most common and easiest method to administer a high 
volume of drug to mice in pre-clinical studies, the rate of absorption from the repository 
site also can be quite slow, due to its main absorption route being the mesenteric vessels.  
In addition, intraperitoneal delivery is subjected to hepatic metabolism before reaching 
systemic circulation, which can lead to drug/molecule modifications
245
.  On the other 
hand, intravenous injection has a rapid dispersion profile into the systemic circulation
243
. 
Thus, differential rates of P188 delivery across the varying routes could help to explain 
the striking differences in functional outcomes observed here. 
 Besides the differential effects shown for the parenteral delivery routes, block 
copolymer molecular weight appears to have a dramatic effect on pharmacodynamics and 
membrane stabilization efficacy. We speculate that differences arising between P188 and 
ext-P188 may be attributable to the propensity of the higher molecular weight ext-P188 
to aggregate. While numerous reports have investigated the relationships of PPO/PEO 
ratio, molecular weight, concentration, and temperature to the aggregation behavior of 
poloxamers in solution
178,217,246,247
, we posit that in vivo aggregation is prohibitively 
difficult to measure and likely complicated by the multi-component nature and space 
constraints of physiological conditions. For ext-P188, the higher dosage (160 mg/kg) 
corresponds to a total blood volume concentration above a reported aqueous critical 
micelle concentration at physiological temperature
246
. If aggregation occurs at the higher 
dosage in vivo, it could explain why ext-P188 was protective at the low dosage (i.e. less 
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likely to aggregate) but not at the high dosage. It is currently unclear how block 
copolymer pharmacodynamics and excretion would be affected by in vivo aggregation 
but these results indicate that molecular weight and concentration are critical components 
of membrane stabilizers to consider for in vivo application. 
 Another interesting outcome of this work centers on the apparent differential 
effect of block copolymer delivery routes to dystrophic cardiac and skeletal muscle.  
Previous work has shown marked efficacy for P188 to confer protection to dystrophic 
myocardium in small and large animal models of DMD in vivo
37,187,234
. These previous 
studies used both IP and IV delivery of P188 to confer protection, which appears 
significantly different from results of this present study where neither of these delivery 
routes were effective to protect dystrophic limb skeletal muscle from contraction-induced 
force loss in vivo.  The basis for these differing results is unknown. Possibilities include 
the marked differences between skeletal and cardiac muscles in terms of physiological 
activation, forces borne, cell size, and in sarcolemma lipid composition.  For example, 
extracellular Ca
2+
 is required for activation of cardiac muscle, but not so for skeletal 
muscles
65
. Also, lengthening contractions are physiologically relevant for skeletal 
muscle, but not for cardiac muscle.  In addition, skeletal and cardiac muscle membranes 
differ dramatically in terms of neutral lipid composition, and dystrophic muscle is known 
to have alterations in membrane phospholipid content
248,249
. Collectively, these striated 
muscle lineage-based differences could help explain the different outcomes observed, in 
terms of route of block copolymer delivery.  Moreover, dystrophic hindlimb tissues have 
markedly lowered microcirculation due, at least in part, to impaired nNOS modulation of 
adrenergic vasoconstriction during contractile activity
40,250
.  Thus, these issues may 
ultimately explain why IV delivery of P188 and ext-P188 is ineffective in protecting 
dystrophic limb muscle against mechanical stress. It is also possible that the minimum 
effective block copolymer content required at the membrane could be fundamentally 
different between cardiac and skeletal muscles.    
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 P188 is a triblock copolymer and member of the family of homologous 
amphiphilic compounds known as Poloxamers (and Pluronics).  P188 has been reported 
for wide use in drug delivery and other biological applications, but virtually nothing is 
known regarding how P188 serves to stabilize fragile dystrophin-deficient muscle 
membranes. Biophysical studies examining triblock copolymer interactions with 
synthetic lipid membranes propose a two-state mechanism of block copolymer 
interaction: initial adsorption followed by insertion into the lipid membrane
169
.  
Membrane insertion appears to be highly dependent on the PPO/PEO ratio of the block 
copolymer, with hydrophobic dominant poloxamers (PPO/PEO > 1) capable of inserting 
and subsequently permeabilizing the cell membrane
167,169
.  In contrast, evidence is 
emerging that the relatively hydrophilic P188 adsorbs onto the lipid membrane and exerts 
membrane stabilization by dampening surface and intra-bilayer hydration dynamics, 
rather than by direct corralling of lipids
212
.  This critical dependence on the PPO/PEO 
ratio is supported by our results showing that the ext-P188, which has the equivalent 
PPO/PEO ratio to P188 at increased molecular weight, significantly stabilizes membranes 
in vitro and also in vivo in a manner dependent on both dosage and delivery route. 
Because efficacy of ext-P188 shows a clear dosage dependence which may be related to 
in vivo aggregation, it is particularly important to keep molecular weight effects in mind 
when considering other polymer species as potential membrane stabilizers.  Moreover, 
the completely hydrophilic PEG8000 lacks efficacy in vivo, indicating that the 
hydrophobic PPO block of the copolymer is required for effective targeting of the 
membrane stabilizer to the damaged membrane. These results provide new mechanistic 
insights into optimal structural design of a potential next-in-class line of block 
copolymers for membrane stabilization therapy which are the target of future studies.  
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2.5  Perspective  
 
 The evidence here that membrane stabilizers can significantly protect dystrophic 
skeletal muscles from contraction-induced injury in vivo may have future clinical 
ramifications.  Presently there are no treatments in clinical practice to prevent, halt or 
reverse disease in DMD patients, including recent drug and gene-based 
strategies
129,130,251
. This underscores the urgency to investigate alternative strategies 
aimed at directly targeting the primary defect of membrane fragility in DMD muscles. 
Synthetic membrane stabilizers have a number of features that make them attractive 
candidates for DMD treatment.  First, the mechanism of action is non-specific to the 
DMD gene mutation, making this applicable to all DMD patients. In addition, systemic 
distribution of block copolymers makes them ideal for treatment of all the striated 
muscles in the body. Immunogenicity concerns of gene-based DMD treatments
252
 are 
also obviated by the use of synthetic sarcolemma stabilizers.   
 Having established proof-of-principle for membrane stabilizers to protect 
dystrophic skeletal muscles in vivo, future studies are needed to ultimately guide their full 
potential clinical application. These include establishing minimum effective dose, 
duration of action, and assessment of long-term protection in small and large animal 
models of DMD.  Importantly, it is the goal to incorporate these current findings with 
recent works in heart and respiratory function, as well as other dystrophic muscle groups.  
In addition, as block copolymers have been in use as vehicles for enhanced gene delivery 
in other applications
246,253
, the prospect of bundled therapies with block copolymers and 
gene-directed strategies is of interest.  P188 offers the additional advantage of being 
previously administered for human use for other conditions, which have been 
accompanied by extensive pharmacokinetics and ADME studies to validate clinical 
safety
176,198
. Our results support P188 as a unique first-in-class membrane stabilizer, as 
any effective DMD treatment must ultimately target all striated muscles: skeletal, 
respiratory and cardiac.   
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 As DMD is a chronic progressive disease, we envision that membrane stabilizer 
therapy would likely require life-long treatment in DMD patients, initiated early in the 
course of disease to prevent mechanical stress-induced muscle damage. In the best case 
scenario, this clinical treatment would effectively manage disease, analogous, for 
example, to the effective life-long disease management strategy demonstrated by Type I 
diabetes patients.  Other approaches could be considered as well, including acute 
treatments.  For example, for DMD patients that undergo surgical orthopedic procedures,  
synthetic membrane stabilizers might also have significant clinical impact in the setting 
of the anticipated stress induced by general anesthesia
187
. Owing to the proposed 
membrane stabilizer mechanism of action, this class of therapeutics has a great advantage 
of potential application to all DMD patients regardless of specific genetic lesion and may 
extend to other inherited and acquired diseases in which sarcolemma integrity is 
compromised
179
. 
 
 
2.6 Methods 
 
Animals. Adult male and female mdx mice (C57Bl/10ScSn-DMDmdx) and wildtype 
BL/10 mice (C57Bl/10ScSn) aged 2-6 months old were obtained from Jackson Labs (Bar 
Harbor, ME) and housed locally. The procedures used in this study were approved by the 
University of Minnesota’s Institutional Animal Care and Use Committee (IACUC). 
 
Generation of control iPax3 satellite cells-derived myotubes. Satellite cells were isolated 
from 6-8 week-old Pax7-ZsGreen mice as described previously
254
. Cell sorting was 
performed on a BD FACSAria cell sorter. Freshly isolated satellite cells were 
immediately transduced with the doxycycline inducible iPax3/IRES mCherry lentiviral 
vector
148
  to generate the iPax3-SCs. Pax3 induction prevented the satellite cells from 
differentiation as soon as they are plated in culture, allowing better expansion of 
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undifferentiated cells in vitro. When iPax3-SCs were subjected to differentiation 
conditions (5% horse serum and withdrawal of dox and bFGF), culture gave rise to 
multinucleated myotubes. 
 
Generation of mdx:utrn
-/- 
iPS cells-derived myotubes.   mdx:utrn
-/-
myotubes were 
generated following a previously published method 
148
. Briefly, dystrophic iPS cells were 
generated from tail tip fibroblasts of mdx:utrn
-/- 
donors and reprogrammed using via 
retroviral transduction with Oct4, Klf-4 and Sox2. The iPS cells were then modified for 
doxycycline-regulated Pax3 conditional expression. Pax3 was induced via 0.8 µg/mL of 
doxycycline from day 3 of embryoid bodies differentiation and paraxial mesoderm 
progenitors were isolated based on PDGFαR expression and lack of Flk-1255.  Sorted cells 
were plated and allowed to proliferate in proliferation myogenic medium (IMDM, 15% 
FBS, 1% chicken embryo extract, 10% horse serum, 1 µg/mL doxycycline and 5 ng/mL 
of bFGF). The myogenic precursors were then terminally differentiated by switching to 
low glucose DMEM and 5% horse serum in the absence of both doxycycline and bFGF.  
 
Flexor Digitorum Brevis single myofiber isolation. The Flexor Digitorum Brevis (FDB) 
muscles were surgically removed from both hind paws of adult mdx mice and 
enzymatically digested via incubation in M199 containing 0.2% collagenase type II plus 
10% fetal bovine serum at 37 °C. Myofiber bundles were dissociated with gentle 
trituration using Pasteur pipettes and myofibers were plated on 20 µg/mL laminin-coated 
coverslips and left to adhere overnight at 37°C in 5% CO2). The myofibers were cultured 
in M199 media (Sigma, St.Louis, MO) supplemented with 10 mmol/L glutathione, 26.2 
mmol/L sodium bicarbonate, 0.02% bovine serum albumin, and 50 U/ml penicillin-
streptomycin, with pH adjusted to 7.4. Myofibers were used within 24 hours of isolation.  
 
  
 63 
 
Block Copolymers.  National Formulary grade of P188, P338 and P331 were generously 
provided by BASF. P338 is denoted as "ext-P188" for simpler interpretation. PEG8000 
(Polyethylene Glycol 8000) was purchased from Sigma (St Louis, MO).  
 
Hypo-osmotic stress assay. FDB myofibers were transferred from M199 culture media to 
a 310 mOsm isotonic solution (in mM: 140 NaCl, 5 KCl, 2.5 CaCl2, 2 MgCl2, and 10 
HEPES; pH 7.2) in the absence or presence of polymer. After a 3 min of pretreatment 
equilibration with the polymer, myofibers were subjected to hypo-osmotic stress for 90 
seconds by exchanging in a 140 mOsm solution (composition equivalent to 310 mOsm 
solution but with NaCl reduced to 50 mM) +/- polymer. The myofibers were 
subsequently re-equilibrated in an isotonic solution +/- opolymer for a total of 7 min. The 
remaining myofibers were lysed with 0.01% Triton. Every media change was collected to 
assess enzyme release throughout the protocol. Enzyme release was assessed as a total 
release during the course of the protocol over total enzyme content.  
 
Enzyme release assays.  Lactate Dehydrogenase (LDH) release was assessed at the end of 
the hypo-osmotic stress protocol. LDH release was assayed by incubating samples 
aliquots in 100mM NaPO4, 120µM NADH, 2.3mM pyruvate, and 0.033% bovine serum 
albumin at 37°C degrees. Absolute LDH release was calculated indirectly from the 
conversion of NADH to NAD+, which was determined by reading absorbance at 340 nm 
over time.  
 
Block copolymer treatment and delivery for in vivo injury protocol. Block copolymers 
were dissolved in sterile saline to final stock solutions of 150 mg/ml. At least 30 min 
before the start of the in vivo injury protocol, mice received specific dosages of 
Poloxamer or equivalent saline volume intraperitoneally (IP), intravenously (IV), 
subcutaneously (subQ - beneath the scruff on the back of the neck) or intramuscularly 
(IM) into the TA muscle.  
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In vivo lengthening contraction force loss protocol. In vivo force measurements of the 
anterior crural muscle compartment (tibialis anterior, extensor digitorum longus and 
extensor hallucis longus) were performed as described previously 
102,237
. Mice were 
anesthetized with a combination of fentanyl citrate (0.2mg/kg), droperidol (10mg/kg) and 
diazepam (5 mg/kg) and the left hindlimb was depilated. The left foot was then secured to 
an aluminum foot-plate coupled to a servomotor (Model 300B-LR;Aurora Scientific, 
Aurora, Ontario, Canada). Contractions were induced via stimulation of the peroneal 
nerve via percutaneously inserted Pt-Ir electrode wires (Model E2-12; Grass 
Technologies, West Warwick, RI, USA) connected to a stimulator and stimulus isolation 
unit (Models S48 and SIU5, Grass Technologies). This system allows for a non-invasive 
evaluation of skeletal muscle contractile properties in vivo 
224
.  An initial pre-injury 
maximal isometric force was determined (250 Hz and 150 ms duration), followed by an 
injury protocol consisting of 50 lengthening contractions. For the lengthening 
contractions, the foot underwent 19 degrees passive dorsiflexion at which a pre-
lengthening 100 ms isometric contraction was initiated followed by another 50 ms of 
stimulation as the foot was actively moved to 19 degrees of plantarflexion (for a total 
ankle rotation of 38 degrees). Each lengthening contraction was separated by 10 seconds 
to prevent fatigue. Maximal force was measured for each lengthening contraction during 
the course of the injury protocol and presented initialized to the first lengthening 
contraction force.  A final isometric force was measured at the end of the lengthening 
protocol. n ≥ 5 mice (both males and females) for each treatment group of each 
experiment.  
 
Evans blue dye uptake assay. To assess the integrity of the muscle fiber membrane pre- 
and post-lengthening contractions, mdx mice (n = 6-8 per experimental group) received 
an intraperitoneal injection of 3% Evans blue dye (EBD; Sigma, St. Louis, MO) (wt/vol) 
in phosphate-buffered saline (PBS, pH 7.4) at a volume of 1% body mass. This solution 
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was sterilized by passage through a Millex-GP 0.22 μm filter (Millipore, Bedford, MA) 
and administered 2h before initiation of the lengthening injury protocol. Both the injured 
and contralateral TA muscles were collected and weighed 2h after injury and dye uptake 
was measured by absorbance reading at 620 nm after dye extraction from the minced 
tissue by incubation in 1 ml formamide at 55°C
63,256
.  A subgroup of injured TA muscles 
was snap-frozen in isopentane cooled with liquid nitrogen, cryosectioned, and visualized 
for red fluorescence as a signal of dye uptake in myofibers. 
 
Statistics. All results are expressed as mean  SEM. Multi-group comparisons for in vitro 
LDH release experiments were assessed using one way analysis of variance (ANOVA) 
with Tukey post-hoc test and P < 0.05 considered statistically different. A two-way 
ANOVA followed by a Bonferroni-post hoc test was used to assess the effect of 
lengthening contraction numbers and treatment routes across the 50 contractions protocol 
with P < 0.05 considered statistically different. All statistical analysis was carried out 
using Prism (GraphPad Software). 
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3.1 Introduction 
 
 The investigation of poloxamers as membrane stabilizing agents has been ongoing 
for decades
165,166,257
. Poloxamers are triblock copolymers composed of a polypropylene 
oxide (PPO) core flanked on each side by polyethylene oxide (PEO) chains. We and 
others have established that one such poloxamer, P188, has biological membrane 
stabilizing capacity in the context of various muscle diseases, including as described in 
Chapter 2, the degenerative disease Duchenne Muscular Dystrophy (DMD)
258
. 
In addition to P188, these copolymers come in various molecular weights and 
PPO/PEO ratios and are constrained, in terms of ease of acquisition, to those made 
available commercially by the chemical company BASF. This limitation is an impetus for 
pushing our exploration of the copolymer chemical landscape beyond that of the triblock 
architecture. In order to intelligently design an optimal membrane stabilizer for DMD, it 
is necessary to increase our understanding of the parameters that control copolymer 
association with muscle membrane bilayers.  
Studies have reported that membrane stabilizing triblock copolymers such as 
P188 are weakly adsorbed to the lipid bilayer
170,212
.  It is hypothesized that this weak 
association is due to poor integration of the PPO unit inside the bilayer due to steric 
constraints imposed by the flanking PEO chains
203
. Removal of one of the flanking PEO 
chains to form a diblock PEO-PPO architecture (Figure 1) allows for assessment of the 
association of the hydrophobic PPO core with the lipid bilayer due to reduction in the 
steric constraints that prevent PPO incorporation amongst the hydrophobic acyl chains.   
A recent study employing small- and wide-angle X-ray scattering examined the 
structure of a lipid bilayer and the phase produced by either the triblock P188 or a PEO-
PPO with an equivalent PPO block length
259
. They observed that P188 interaction with a 
synthetic lipid bilayer produced an aggregate phase structure suggesting inadequate 
insertion of the polymer in the lipid bilayer. On the other hand, the PEO-PPO diblock 
produced a well-ordered lamellar phase indicative of being well-anchored in the 
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bilayer
259
. This suggests that removing one of the flanking PEO chains facilitates PPO 
block anchoring into the hydrophobic acyl chain region of the lipid bilayer and 
strengthens copolymer-bilayer interaction.  
In addition to decreasing steric constraints to increased PPO interaction with the 
hydrophobic region of the bilayer, removal of one of the flanking PEO chains allows for 
more straightforward additions of end-group moieties to the PPO block. This capability 
allows us to investigate in greater depth, the role of the PPO block in interacting with the 
bilayer. Specifically, we can now strategically modulate PPO block hydrophobicity by 
addition of relatively hydrophobic small end groups as a means to fine tune diblock-
bilayer interactions. 
There is currently little known on the physio-chemical basis of PEO-PPO diblock 
copolymer interaction with lipid bilayers in vitro, and even less so under physiological 
conditions.  The objectives of this work were to demonstrate, for the first time to our 
knowledge, that diblock PEO-PPO architectures are effective membrane stabilizers for 
DMD, and that both PPO/PEO composition and PPO end group chemistry play crucial 
roles in optimizing membrane stabilization.  
 
Figure 1: Copolymer structures for PEO-PPO-PEO triblocks, PEO-PPO diblocks and PEO 
homopolymer.  The hydrophilic PEO chain is represented in blue and hydrophobic PPO core is 
represented in red.  
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A PEO-PPO diblock architecture became a focus of investigation due to 1) a 
simpler synthesis process that allows for methodical changes to composition and 
molecular weight, 2) gaining insight into whether a triblock architecture is required for 
membrane stabilization, and 3) allowing for addition of end groups moieties to either 
PEO and/or PPO blocks to alter overall diblock chemistry and membrane interaction.   
 This work is the result of collaboration with Professor Frank Bates' group in the 
department of chemical engineering and materials science (CEMS) at the University of 
Minnesota. Diblock copolymers were designed and synthesized by Dr. Karen Haman and 
graduate student Wenjia Zhang. Dr. Mihee Kim helped collect and analyze part of the in 
vitro data. 
 
 
3.2  Role of architecture in membrane stabilization: triblock vs. diblock 
comparison 
 
 Little is known, to our knowledge, about whether or not diblock architectures can 
stabilize biological membranes in vitro or in vivo. Due to the established membrane 
stabilization activity of Poloxamer 188
165,37,187,234,258
, direct comparison was first made 
with its composition analog diblock (di-80%), which was purchased from Polymer 
Source (Montreal, Quebec). In this case, the two copolymers share the same PPO/PEO 
composition ratio and hydrophilic PEO chain length (Table 1).  Of note, the terminal 
PPO end group on the di-80% is a methoxy group (-mE) (Figure 1), which role will be 
addressed in a later part of the study. We also tested PEG8000 as a negative control as we 
have demonstrated previously in Chapter 2 that PEO alone is not sufficient for optimal 
membrane stabilization. 
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Copolymer 
Average MW 
(Da) 
Total 
PEO 
PPO PPO/PEO 
P188 8400 2 x 75 30 0.19 
di-80% 4200 75 16 0.20 
PEO8000 8000 - - - 
 
Table 1:  Polymer characteristics for P188, the diblock of P188 (di-80%) and PEG8000 
 
First, we tested whether di-80% can stabilize muscle membranes in vitro, 
bypassing any potential pharmacokinetics/dynamics effects on the molecule, which we 
established in Chapter 2 are important factors affecting in vivo efficacy. The principal 
objective of this work was to then assess and compare di-80% and its triblock analog 
P188 in terms of efficacy in preserving dystrophic skeletal muscle function and 
sarcolemmal integrity in vivo. 
 
Di-80% has in vitro membrane stabilizing efficacy comparable to P188  
 
We used our established membrane injuring hypo-osmotic stress assay
258
 to 
compare the efficacy of di-80% and P188 in preventing stress-induced lactate 
dehydrogenase (LDH) release from cardiac myocytes and skeletal myoblasts (Figure 2).  
In rat cardiac myocytes exposed to hypo-osmotic stress, 150 uM P188  decreased LDH 
release (~40% decrease, *P < 0.0001) (Figure 2B).  Similarly, P188 significantly 
decreased LDH in control skeletal myoblasts release (~80% decrease, *P < 0.0001), as 
expected
258
 (Figure 2C). Di-80% at 150 uM shows comparable membrane stabilization 
as P188 in cardiomyocytes (~40% decrease in cardiomyocytes, *P = 0.0002).  In contrast, 
di-80% was significantly less effective than P188 in stabilizing skeletal myoblasts (~65% 
decrease compared to ~85% for P188, P = 0.0009). Interestingly, the completely PEO 
based PEG8000 decreased LDH release in rat cardiomyocytes to the same extent as P188 
and di-80% (~40% decrease, *P = 0.0024) but was not as effective in blocking LDH 
release from skeletal myoblasts. These results indicate that di-80% is not as effective a 
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membrane stabilizer as P188 in skeletal myoblasts, at least in the context of hypo-osmotic 
stress. 
 
Figure 2:  In vitro hypo-osmotic stress assay to compare P188 and its analog diblock di-80% 
for membrane stabilization. (A) Schematic of P188, di-80%, and the exclusively PEO-based 
polymer PEG8000, showing relative PPO (red) and PEO composition (blue).  (B) Rat adult 
cardiomyocytes were exposed to hypo-osmotic stress media in the presence of 150 uM 
copolymers and LDH release was measured as a marker of membrane permeability. (*P < 0.05, 
via one-way ANOVA compared to non-treated).  (C)  LDH release from C2C12 myoblasts 
exposed to hypo-osmotic stress in the presence of 150 uM copolymers (*P < 0.0001, via one-way 
ANOVA compared to non-treated group).  Mean values are derived from at least 3 independent 
experiments. Error bars shown as mean +/- S.E.M.  The myoblasts data were collected and 
analyzed by Dr. Mihee Kim, from the Department of Chemical Engineering and Material 
Sciences at the University of Minnesota. 
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Effects of Di-80% as a muscle membrane stabilizer in vivo  
 
The mdx mouse exhibits significant susceptibility to lengthening contraction 
injury, as evidenced by a marked force loss after successive lengthening 
contractions
36,258
. We have established in Chapter 2 that it is an outstanding 
physiological assay to evaluate the impact of membrane stabilizers in vivo. In brief, the 
hind paw of each mouse was secured to a foot plate connected to a servomotor which 
allowed for controlled plantarflexion and dorsiflexion of the hind limb about the ankle 
joint. Lengthening contractions of the anterior crural muscle compartment were induced 
via electrical stimulation of the common peroneal nerve and the resulting torque from 
each lengthening contraction was measured. We therefore used this assay to evaluate the 
impact of di-80% treatment on physiological muscle function of the hindlimb anterior 
crural muscle group (dorsiflexors) in comparison against its established membrane 
stabilizing triblock analog, P188.   
As demonstrated in Chapter 2, subcutaneously (subQ) delivery of P188 results in 
significant protection against force loss during the lengthening contraction injury 
protocol. In contrast, di-80% delivered subcutaneously shows no improvement in force 
maintenance (Figure 3A). Di-80% showed a trend of improvement as compared to P188 
using intraperitoneal delivery (Figure 3B) but not to a significant extent. Considering di-
80% appears as efficacious as P188 in vitro, it is surprising that a lack of efficacy is 
observed in vivo.  While it remains unclear why a differential effect is seen, the 
pharmacodynamics of both molecules appear different and either not enough or no di-
80% copolymer at all reaches the injured muscle tissues following subQ or IP injection. 
As previously demonstrated in chapter 2, when comparing P188 to its PEO homopolymer 
analog PEG8000, the PPO core seems to drive membrane stabilizing efficacy in vivo. We 
speculate that PPO core length drives copolymer targeting to the injured membrane, 
which could explain why di-80% is as efficacious as P188 in vitro where there are no 
impediment to membrane interaction but lacks efficacy once injected into the body.  
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Figure 3: Comparison of intraperitoneal delivery of di-80% vs. P188 against lengthening 
contraction-induced force loss in mdx mice in vivo.  Force loss by the anterior crural muscles, 
in adult mdx mice (n = 3-8 per group) treated with (A) 460 mg/kg P188 or di-80% subcutaneously 
(subQ) and (B) 1000 mg/kg P188, di-80% intraperitoneally (IP) at least 30 min before the injury 
protocol, was assessed over the course of 50 lengthening contractions.  Force loss is presented as 
a fraction of the initial maximal force +/- S.E.M. Contractions #1-15 show the marked force 
deficit in mdx mice. Results from BL/10 control mice injected with saline are also shown. Inset 
shows all 50 contractions.  
 
 
3.3  Role of PPO end groups in diblock membrane stabilization efficacy 
 
 The elimination of one of the PPO flanking PEO chains allows for end group 
modification of the PPO core itself. As the PPO hydrophobicity is speculated to drive 
membrane efficacy, we wanted to study the impact of adding small end groups of varying 
hydrophobicity on membrane stabilization.  
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Diblocks with two different end group moieties on the PPO block were 
synthesized: tert-butoxy- and hydroxyl- functional blocks (Schematic 1, Figure 4). A 
third end group was also evaluated, as the commercially available diblock of P188 
features a methoxy functional group on the PPO block, which is relatively less 
hydrophobic than a tert-butoxy group but more hydrophobic than a hydroxyl group (tert-
butoxy > methoxy > hydroxyl). 
 To generate a tert-butoxy functionalized diblock (PEOa-PPOb-t), PPO was grown 
from a tert-butoxide initiator and its attached PEO was terminated with a hydroxyl group 
(scheme 1, A, B). Another diblock with a hydroxyl functionalized diblock (PEOa-PPOb-
OH) was generated from commercially from mono-methoxy PEO (scheme 1, A, B).  
While a methoxy group is present in the initial PEO starting block rather than an 
hydroxyl group, its low hydrophobicity relative to the size and hydrophilicity of the PEO 
group makes it relatively inert and it is therefore not expected to affect membrane 
interactions. Representative structures of the tested diblocks are shown in Figure 4.  
 
 
 
Schematic 1: Synthesis of diblock PPO-PEO copolymers.  (A) Initiation, propagation and 
termination of PPO. (B) Re-initiation of tert-butoxy terminated PPO and living anionic 
polymerization of ethylene oxide (EO) to form a PEO-PPO-t-butoxy diblock. (C) Formation of a 
PEO-PPO-OH diblock. Adapted from schematic by Dr. Karen Haman. 
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Figure 4:  Schematic of diblock PEO-PPO copolymers with hydroxyl (OH), methoxy (mE) and t-
butyl (tert) terminated end groups on the hydrophobic PPO (red).  
 
 Two pairs of diblocks were evaluated. The first pair includes the P188 diblock 
analog, di-80%, which we previously mentioned was obtained commercially. The 
industrial synthesis scheme resulted in a methoxy terminated di-80%, which adds a 
slightly higher hydrophobic character to the PPO core compared to the normally hydroxyl 
terminated PEO end blocks of P188.  To compare and contrast the effect of additionally 
increasing the relative hydrophobicity of the PPO core, a tert-butoxy di-80% diblock was 
generated. In addition, to determine whether a PPO/PEO ratio of ~0.20 (or 80% PEO 
composition) was absolutely critical to optimal membrane stabilization, a diblock 
containing the same PPO core length (N = 16) as di-80% but of smaller PEO chain was 
synthesized, resulting in a PPO/PEO ratio of 0.33. This diblock (di-70%) was then 
terminated with either a hydroxyl or a tert-butoxy end group. The tested diblocks are 
listed in Table 2. 
 
 
Copolymer Average MW (Da) PEOb PPOa PPO/PEO 
di-80%-methoxy 4200 75 16 0.21 
di-80%-t-butoxy 4350 75 16 0.21 
di-70%-OH 2900 48 16 0.33 
di-70%-t-butoxy 3000 48 16 0.33 
 
Table 2. Summary of polymer structures of tert-butoxide (t), methoxy (mE), and hydroxyl (OH) 
terminated PEO-PPO diblocks. 
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Effects of PPO end groups and PPO/PEO ratio on membrane stabilization in vitro 
 
 Once again, to  assess membrane stabilization efficacy independently of any 
pharmacokinetics/dynamics effects, the capability of diblock copolymers, with either tert-
butoxy (tert), methoxy (mE), or hydroxyl (OH) end groups to protect muscle cells from 
hypo-osmotic stress in vitro, was investigated (Figure 5).   
 
Figure 5.  In vitro hypo-osmotic stress assay to screen diblock copolymers for membrane 
stabilization.  LDH release from C2C12 myoblasts exposed to hypo-osmotic stress (*P < 0.0001, 
via one-way ANOVA compared to non-treated group) in the presence of 150 uM copolymers.  
Mean values are derived from at least 3 independent experiments. Error bars shown as mean +/- 
S.E.M.  These data were collected and analyzed by Dr. Mihee Kim, from the Department of 
Chemical Engineering and Material Sciences at the University of Minnesota. 
 
As expected and as observed in skeletal myoblasts (Figure 2), enzyme release 
was significantly blocked by the presence of P188, whereas the PEO homopolymer 
PEG8000 had no significant membrane stabilization effect. As demonstrated in skeletal 
myoblasts earlier in this study, the commercial di-80%-mE at 150 uM also had significant 
protection against hypo-osmotic stress induced released of LDH (~60% decrease) but it 
was not as protective as P188 (P= 0.013).  Interestingly, replacement of the methoxy 
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group by a more hydrophobic tert-butoxy trends towards improving enzyme blocking 
efficacy, although it was not significant.  
On the other hand, both hydroxyl and tert-butoxy di-70% diblocks were 
significantly protective, with no difference in efficacy observed between the two different 
end groups. Also, membrane stabilizing efficacy observed with a diblock of 0.33 
PPO/PEO ratio is evidence that a ~0.20 PPO/PEO ratio of the well-established membrane 
stabilizer P188, is not necessarily the “sweet spot” for membrane stabilization efficacy 
and that diblock hydrophobicity can be modulated for increased membrane stabilization. 
 
The tert-butoxy PPO end group significantly potentiates membrane stabilization during 
lengthening contraction injury in vivo 
 
 We next assessed the impact of the PPO functional end group on membrane 
stabilization in vivo. Due to preliminary experiments showing efficacy of intraperitoneal 
(IP) delivery of 1000 mg/kg of the tert-butoxy diblocks, this delivery route and dosage 
was used for PPO end group comparison purposes.  
 When comparing composition analog diblocks that differ only on terminal end 
group chemistry, the t-butoxy functional diblock copolymers exhibited marked protection 
against lengthening contraction injury (Figure 6). In stark contrast, their hydroxyl- and 
methoxy-terminated analogs, which showed significant membrane stabilization efficacy 
in vitro (Figure 5), had no significant protective effect in vivo.  Relative to the hydroxyl- 
and methoxy-terminated end groups, the tert-butoxy group imparts considerably more 
hydrophobicity to the PPO core of the diblock.  These data suggest that the overall 
hydrophobic strength of the hydroxyl and methoxy-terminated PPO group is not 
substantial enough to improve membrane stabilization in vivo, but that further increase in 
hydrophobic character via substitution of a t-butoxide group significantly changes the 
membrane stabilization property of the copolymer.   
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Figure 6: Comparison of methoxy vs t-butoxy end groups of di-80% against lengthening 
contraction-induced force loss in mdx mice in vivo.  (A) Force loss by the anterior crural 
muscles, in adult mdx mice (n = 4-7 per group) treated with 1000 mg/kg of each di-80% diblock 
or saline vehicle intraperitoneally at least 30 min before the injury protocol, was assessed over the 
course of 50 lengthening contractions.  Force loss is presented as a fraction of the initial maximal 
force +/- S.E.M. Contractions #1-15 show the marked force deficit in mdx mice. Results from 
BL/10 control mice injected with saline are also shown. Inset shows all 50 contractions.  (B) The 
methoxy-terminated di-80%  had no significant effect on peak isometric force immediately after 
injury whereas the t-butoxide terminated di-80%  treatment significantly enhanced immediate 
postinjury isometric force recovery compared to mdx saline, and was not significantly different 
from BL/10 saline group. 
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Figure 7: Comparison of hydroxyl vs t-butoxy end groups of di-70% against lengthening 
contraction-induced force loss in mdx mice in vivo.  (A) Force loss by the anterior crural 
muscles, in adult mdx mice (n = 4-7 per group) treated with 1000 mg/kg of each di-70% or saline 
vehicle intraperitoneally at least 30 min before the injury protocol, was assessed over the course 
of 50 lengthening contractions. Force loss is presented as a fraction of the initial maximal force 
+/- S.E.M. Contractions #1-15 show the marked force deficit in mdx mice. Results from BL/10 
control mice injected with saline are also shown. Inset shows all 50 contractions.  (B) The 
hydroxyl-terminated di-70% had no significant effect on peak isometric force immediately after 
injury while the t-butoxide terminated di-70% treatment trended towards enhanced immediate 
postinjury isometric force recovery compared to mdx saline, and was not significantly different 
from BL/10 saline group. *P < 0.05 one-way analysis of variance compared to mdx saline, #P < 
0.05 one-way analysis of variance compared to BL/10 saline. Error bars shown as mean ± 
standard error of the mean. 
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3.4  Discussion 
 
This study is the first mechanistic investigation into the structure-function 
relationship of block copolymer architecture in terms of defining the basis of copolymer-
based membrane stabilization in live cells under physiological conditions. Our results 
provide new evidence that synthetic diblock PEO-PPO copolymers have biological 
membrane stabilization efficacy both in vitro and in vivo.  First, we provide new insight 
into block copolymer architecture in terms of membrane stabilization properties. We 
show for the first time that a triblock architecture is not required for effective membrane 
stabilization. This result is important as it opens a new structure-function avenue 
featuring smaller and easier to synthesize membrane stabilizing diblock copolymers. In 
addition, the PEO-PPO diblock architecture allows ready access to PPO block end group 
modifications. We demonstrate that membrane stabilization in vivo can be optimized via 
modulation of the PPO block end group chemistry. Our results underscore the striking 
effect of the hydrophobic PPO core terminal end group to membrane interaction and 
stabilization in vivo.  To account for these new findings, we propose an "anchor and 
chain" working model of copolymer-membrane interaction (Figure 8), as detailed below. 
We report here that the addition of a hydrophobic tert-butoxy end group to the 
PPO core confers significantly improved membrane protection to dystrophic limb skeletal 
muscles during in vivo mechanical stress. In stark contrast, while substitution of either the 
relatively less hydrophobic methoxy terminal end group or the hydrophilic hydroxyl end 
group to the PPO core still imparts membrane stabilization efficacy in vitro, efficacy is 
completely lost in vivo.  It remains unclear why the relative strength of hydrophobicity of 
the PPO end group induces the diblock copolymer to exhibit markedly differential effects 
in vivo. Nevertheless, these findings underscore the importance of modulating the 
hydrophobicity of the PPO block to enhance interaction with the membrane bilayer and 
indicate that the PPO block is the driving component for membrane interaction and 
stabilization in vivo. 
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Compared to the hydrophobicity of the alkyl tails of a phospholipid membrane 
bilayer, PPO itself is relatively mildly hydrophobic. This mismatch in hydrophobicity is 
hypothesized to lead to arrangement of the PPO at the polar lipid heads and hydrophobic 
alkyl chain tails border rather than full insertion into the alkyl chain region of the 
bilayer
259,260
. Further penetration at significantly increased overall copolymer 
hydrophobicity would lead to disruption of the lipids and membrane lysis, such as 
observed with copolymers with high PPO/PEO ratios
208,261.  We propose an “anchor and 
chain” model (Figure 8) whereby the addition of a relatively hydrophobic but small end 
group “anchor”, as demonstrated by tert-butoxy, increases the hydrophobic character of 
the PPO core without significantly increasing its overall hydrophobicity of the 
copolymer, leading to an "anchoring" of the PPO core at the alkyl tail region of the 
bilayer. On the other hand, the PEO chain is required to preserve the amphiphilic 
behavior of the copolymer to maintain it at the solvent-membrane interface (Figure 8).   
 
Figure 8:  Schematic of triblock vs diblock copolymer interactions with a lipid bilayer. In 
this “anchor and chain” hypothesis, the t-butyl terminated end group on the hydrophobic PPO 
block (red) anchors the diblock copolymer within the hydrophobic region of the bilayer. The PEO 
block (blue) is the chain required to prevent further penetration and subsequent lysis of the 
bilayer. 
 
 Moreover, these results suggest that the length of the PEO block is not a critical 
factor beyond imparting enough hydrophilicity to the copolymer to maintain its 
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PPO/PEO ratio below a critical point above which complete insertion and membrane 
lysis would occur. In contrast, related studies demonstrated that the length of the PPO 
block determines the nature of copolymer association with the membrane
203,260
, with 
longer PPO block inducing insertion into damaged lipid membranes at lower surface 
pressures
167
. This suggests that for effective membrane stabilization, the second PEO 
chain in the triblock architecture is redundant as long as a minimum PEO length is 
maintained to keep the molecule at the head group/acyl chains interface, and that the 
extra flanking PEO chain in the triblock architecture imposes steric constraints that 
weakens copolymer-bilayer interactions and increases water solubility of the PPO 
block
259
. This indicates that effective membrane stabilizing diblock copolymers can be 
synthesized with both smaller PPO and PEO block sizes, resulting in a smaller overall 
molecule.  
 We demonstrated in Chapter 2 that pharmacokinetics and pharmacodynamics of 
copolymers appear to vary depending on route of delivery, copolymer molecular weight, 
and PPO/PEO ratio. In this study, we chose to deliver the diblock copolymers using 
intraperitoneal delivery due to observed protective effects of all the tested tert-butoxy 
diblocks via this route. Keeping the delivery and dosage constant, the role of the PPO end 
group could be teased apart independently of delivery. Nonetheless, it is unclear whether 
varying delivery routes would influence the results obtained and further work is under 
consideration to reconcile pharmacokinetics/dynamics to copolymer structure and 
composition. 
 
 
3.5  Perspective 
 
 Very little is known in the copolymer based membrane stabilization literature 
beyond studies of commercially available PEO-PPO-PEO triblocks. We demonstrate here 
for the first time the efficacy of a diblock architecture in stabilizing injured biological 
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membranes. The diblock architecture offers several advantages, including an easier and 
more controlled chemical synthetic process allowing to more precisely control PPO and 
PEO block sizes, as well as the ability to substitute various functional end groups to the 
hydrophobic PPO core for membrane interaction. This latter benefit allows for sensitive 
manipulation of the diblock PPO block hydrophobicity for optimal membrane interaction 
and stabilization. In addition, substitution of a PPO block with other chemistries could be 
considered, such as a relatively more hydrophobic polybutylene oxide block (PBO). 
These exciting proof-of-principle results establish physiological relevance to diblock 
copolymers and support further investigation of the copolymer chemical space. 
 
 
3.6 Methods 
 
Animals. Adult male and female mdx mice (C57Bl/10ScSn-DMDmdx) and wildtype 
BL/10 mice (C57Bl/10ScSn) aged 2-8 months old were obtained from Jackson Labs (Bar 
Harbor, ME) and housed locally. The procedures used in this study were approved by the 
University of Minnesota’s Institutional Animal Care and Use Committee (IACUC). 
 
Ventricular rat cardiomyocytes isolation. 
Adult rat ventricular myocyte isolation was performed as previously described
262,263
. 
Briefly, adult female rats were anaesthetized by inhalation of isoflurane followed by i.p. 
injection of heparin (1500 U/kg) and Nembutal (162.5 U/kg). Following enzymatic 
digestion by retro-grade perfusion with collagenase and gentle trituration of the cardiac 
ventricles, cardiac myocytes were plated on laminin-coated glass coverslips (2x10
4
 
myocytes/coverslip) and cultured in M199 media (Sigma, supplemented with 10 mmol/L 
glutathione, 26.2 mmol/L sodium bicarbonate, 0.02% bovine serum albumin, and 50 
U/ml penicillin-streptomycin, with pH adjusted to 7.4, additionally insulin (5μg/ml), 
  
 84 
 
transferrin (5μg/ml) and selenite (5ng/ml) (ITS) were added (Sigma I1884)). Myofibers 
were used within 24 hours of isolation.  
 
Myoblast cell culture 
Mouse muscle myoblasts (C2C12; American Type Culture Collection, Manassas, VA) 
were grown in cell growth media consisting of high glucose DMEM (Gibco Invitrogen, 
Grand Island, NY), 20% fetal bovine serum (Gibco Invitrogen, Grand Island, NY) and 
1% Penicillin/Streptomycin (Gibco Invitrogen, Grand Island, NY) at 37
o
C humidified 
atmosphere of 5% CO2. At 70% confluency, cells were split in order to prevent partial 
differentiation due to cell-cell contact. The cell culture media was replaced every two 
days. 
 
Block Copolymers.   
National Formulary grade of Poloxamer 188 was generously provided by BASF 
(Pluronic F68, Wyandotte, MI),and its diblock analog (Di-80%) was purchased from 
Polymer Source (P1862-EOPO, Montreal, Quebec). PEO-8k was purchased from Sigma, 
St.Louis, MO). 
 
Diblock copolymer synthesis. Synthetic methods for PEO-PPO diblocks using sequential 
anionic polymerization are well established (refs).  In brief, PPO was first initiated and 
propagated using tert-butoxide (from potassium tert-butoxide) as the reaction initiator 
(scheme 1). The use of 18-crown-6 ether to complex with potassium counter ions 
resulting from the tert-butoxide initiation has been shown to be a catalyst for the 
propagation step of PPO thereby limiting the polydispersity of the resulting copolymer 
(refs).  Following a purification and characterization step, the polyethylene oxide chain 
was grown from the propylene oxide block by living anionic polymerization of ethylene 
oxide after reinitiating the monohydroxyl terminated PPO starting block with potassium 
naphthalenide. The reaction was then terminated with excess acidic methanol solution 
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and the resulting diblock copolymer recovered by solvent removal. Following filtration, 
dialysis and drying, the resulting purified copolymers were characterized and confirmed 
by size exclusion chromatography and H
1
 NMR. 
 
Polymer Characterization. Polymers were characterized by size exclusion 
chromatography (SEC, Waters) equipped with a refractive index detector and 
tetrahydrofuran as the solvent to determine dispersity (Ð), and 1H NMR (Bruker AV-500 
in deuterated chloroform, CDCl3) was used to determine block compositions. 
 
Hypo-osmotic stress assay. Rat cardiomyocytes were transferred from M199 culture 
media to a 310 mOsm isotonic solution (in mM: 140 NaCl, 5 KCl, 2.5 CaCl2, 2 MgCl2, 
and 10 HEPES; pH 7.2) in the absence or presence of 150 uM copolymer. After a 3 min 
of pretreatment equilibration with the polymer, cardiomyocytes were subjected to hypo-
osmotic stress for 90 seconds by exchanging in a 170 mOsm solution (composition 
equivalent to 310 mOsm solution but with NaCl reduced) +/- copolymer. The 
cardiomyocytes were subsequently re-equilibrated in an isotonic solution +/- copolymer 
for a total of 7 min. The remaining cardiomyocytes were lysed with 0.01% Triton X-100. 
For myoblasts screening, around 10
4
 cells were inoculated into a 96 well plate and grown 
to cover enough well plate surface. When ready to use, the cells were transferred from the 
growth media to a 310 mOsm isotonic buffer +/- copolymer. After incubating for 30 min, 
the cells were subjected to hypo-osmotic stress by exchanging the isotonic buffer to 133.5 
mOsm hypotonic buffer +/- copolymer for 50 min. The cells were subsequently re-
equilibrated in an isotonic buffer +/- copolymer for 30 min. Finally, the cells were lysed 
with 0.01% Triton X-100. In every buffer exchange step, the buffer pulled out of the well 
was collected and stored at 4 
o
C before being used for enzyme release assay. 
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Enzyme release assays.  Lactate Dehydrogenase (LDH) release was assessed at the end of 
the hypo-osmotic stress protocol. LDH release was assayed using a kit from Pointe 
Scientific (Canton, MI).    
 
Block copolymer treatment and delivery for in vivo injury protocol. Block copolymers 
were dissolved in sterile saline to final stock solutions of 150 mg/ml. At least 30 min 
before the start of the in vivo injury protocol, mice received specific dosages of 
Poloxamer or equivalent saline volume intraperitoneally (IP) or subcutaneously (subQ - 
beneath the scruff on the back of the neck). 
 
In vivo lengthening contraction force loss protocol. In vivo force measurements of the 
anterior crural muscle compartment (tibialis anterior, extensor digitorum longus and 
extensor hallucis longus) were performed as described previously 
102,237
. Mice were 
anesthetized with a combination of fentanyl citrate (0.2mg/kg), droperidol (10mg/kg) and 
diazepam (5 mg/kg) and the left hindlimb was depilated. The left foot was then secured to 
an aluminum foot-plate coupled to a servomotor (Model 300B-LR;Aurora Scientific, 
Aurora, Ontario, Canada). Contractions were induced via stimulation of the peroneal 
nerve via percutaneously inserted Pt-Ir electrode wires (Model E2-12; Grass 
Technologies, West Warwick, RI, USA) connected to a stimulator and stimulus isolation 
unit (Models S48 and SIU5, Grass Technologies). This system allows for a non-invasive 
evaluation of skeletal muscle contractile properties in vivo 
224
.  An initial pre-injury 
maximal isometric force was determined (250 Hz and 150 ms duration), followed by an 
injury protocol consisting of 50 lengthening contractions. For the lengthening 
contractions, the foot underwent 19 degrees passive dorsiflexion at which a pre-
lengthening 100 ms isometric contraction was initiated followed by another 50 ms of 
stimulation as the foot was actively moved to 19 degrees of plantarflexion (for a total 
ankle rotation of 38 degrees). Each lengthening contraction was separated by 10 seconds 
to prevent fatigue. Maximal force was measured for each lengthening contraction during 
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the course of the injury protocol and presented initialized to the first lengthening 
contraction force.  A final isometric force was measured at the end of the lengthening 
protocol. n ≥ 5 mice (both males and females) for each treatment group of each 
experiment.  
 
Statistics. All results are expressed as mean  SEM. Multi-group comparisons for in vitro 
LDH release experiments were assessed using one way analysis of variance (ANOVA) 
with Tukey post-hoc test and P < 0.05 considered statistically different. A two-way 
ANOVA followed by a Bonferroni-post hoc test was used to assess the effect of 
lengthening contraction numbers and treatment routes across the 50 contractions protocol 
with P < 0.05 considered statistically different. All statistical analysis was carried out 
using Prism (GraphPad Software). 
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4.1 Introduction 
  
 The investigation of the triblock copolymer poloxamers has generated significant 
attention as they have been demonstrated to be of use in a broad range of biomedical 
applications, including as biological membrane interacting molecules
166,169,201
.  
Poloxamers are a class of amphiphilic triblock copolymers composed of a polyethylene 
oxide (PPO) core flanked on both sides by linear chains of polyethylene oxide (PEO). 
Poloxamers   have been designed with specific modifications in overall molecular weight 
and in the relative PPO/PEO ratio.  These two parameters are hypothesized to be critical 
elements underlying how copolymers modulate membrane interactions, as well as 
affecting poloxamer solubility
167,209
. These features make poloxamers highly 
customizable for specific industrial uses or for potential biomedical applications. 
Poloxamer 188 (P188) is of particular biomedical interest as a membrane 
stabilizer.P188 has been found beneficial in an extensive range of clinical conditions of 
membrane injury, including electrical shock
191
, irradiation
182,183
, thermal burns
181
, and 
other diseases that affect cell membrane integrity
264,176,193,257,265,266
. Of particular interest 
to us, we have established in Chapter 2 and 3 that P188 acts as membrane stabilizer in the 
context of muscle membrane mechanical disruptions such as in Duchenne muscular 
dystrophy
37,187,195,234,258
.        
Biological membranes function as the boundary between the cellular cytoplasm 
and the cell's extracellular environment to maintain cellular homeostasis. The membrane 
to extracellular fluid interface plays an important role in many biological and 
pharmacological phenomena. Membrane bilayers are composed of amphiphilic lipid 
molecules held together via hydrophobic bonds between their acyl chains and hydrophilic 
interactions between their head groups. These relatively weak intermolecular interactions 
influence the fluidity and packing of the whole membrane.  
When considering a triblock copolymer such as P188 interacting at the membrane 
interface, there are three types of copolymer/lipid interactions: 1) interaction of the 
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copolymer with the lipid head groups; 2) interaction with the hydrophobic alkyl chains; 
or 3) interactions with both head groups and acyl chains. The latter two types of 
interactions require the copolymer to penetrate past the head group region to access the 
hydrophobic region of the bilayer. In addition, the copolymer hydrophobic and 
hydrophilic chains can interact with themselves considering the relatively hydrophobic 
PPO core would in theory minimize its own solvent accessible area. 
Despite previous investigations on poloxamers, and specifically their   
interactions with lipid membranes, it remains unclear what is the mechanism of 
interaction and the driving force behind these interactions.  Studies using lipid 
monolayers spread on a Langmuir trough demonstrate that copolymers insert into areas of 
low lipid density at low surface pressures and disorders the lipid packing
201,202
.  Another 
study found that adsorption of copolymers to liposome-based lipid bilayers induce 
considerable disordering of the lipid packing and enhanced membrane permeability
164
 
whereas another study posited  that insertion and not adsorption disorders lipid 
packing
212
.  
More recent studies demonstrate that copolymer interaction with a lipid bilayer 
involves initial adsorption at the polar head group level, followed by insertion inside the 
bilayer
170,210,212
, and that insertion is dependent on temperature, copolymer solubility, and 
PPO block length
209
. Moreover, several studies provide evidence that adsorption of the 
copolymer does not affect lipid diffusion, whereas insertion hinders lipid diffusion
209
 and 
increases lipid packing
210
.  These inconsistencies likely arise from experimental studies 
employing different models of lipid membranes (monolayers
202
, bilayers
267
 or unilamellar 
vesicles
169
) and different experimental methods of measurement (Langmuir 
isotherms
201,202
, X-ray scattering
168
 methods, isothermal calorimetric measurements
210
, 
and fluorescence microscopy
169,201
).  
Understanding the fundamental interactions of block copolymers with the 
biological membrane interface has critical implications in designing and optimizing 
membrane stabilizing copolymers structure. In this regard, molecular dynamics (MD) 
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simulations have been well established as a method of choice to probe both location and 
dynamics of membrane active molecules such as small molecule drugs
268
 and 
fluorophores
269
 that cannot readily be observed with experimental techniques.  
 As of today, there are few reports detailing molecular dynamic simulations to 
study poloxamer-membrane interactions
167,208,226,227
. Growing efforts directed to the 
computational study of copolymer-lipid interactions have mostly applied Monte Carlo 
and coarse-grained molecular dynamics. These allow for larger timescale simulation, but 
give only a partial and representative view of the membrane structural properties with 
loss of atomic resolution information, reduced number of degrees of freedom, and 
inaccuracy in describing the subtle dynamics of the system. Other studies using all-
atomistic resolution simulations have so far only investigated small and highly 
hydrophobic triblock copolymers
208
. 
Here we use all-atomistic MD simulations to provide new molecular insights into 
how membrane stabilizing copolymers, principally P188, interact with the membrane 
bilayer in the context of increased membrane permeability. All-atomistic MD simulations 
are superior to coarse-grained models as they give atomistic level resolution and more 
detailed mechanistic insight. We use here a 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) bilayer as a model lipid bilayer as it is one of the most extensively studied 
phospholipids, both experimentally
168,201,261
 and computationally
270–273
. Model synthetic 
membranes lack the typical structural complexity of native membranes, as they do not 
precisely replicate all aspects of a living biological cell membrane. Nonetheless, they 
have been demonstrated and recognized as an invaluable tool for understanding 
molecular-level biophysical interactions of polymer-lipid bilayer systems.  
We evaluated in a first system, the effect of lipid bilayer surface tension changes 
on P188-bilayer interactions. The rationale for using increases in surface tension to 
induce altered membrane fluidity/permeability is based on a study using coarse-grained 
MD to simulate the effects of surface tension on the structure and properties of the DPPC 
bilayer by evaluating its area-per-lipid, lipid-order parameters, membrane thickness, and 
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lipid-molecule planar diffusion
274
.  In that study, an increase in the applied surface 
tension of the bilayer resulted in a significant increase in the area-per-lipid, and therefore 
an increased fluidity of the bilayer, as well as increased lipid lateral diffusion and 
decreased lipid-tail order. Similar results showing the effect of increasing surface tension 
on the bilayer area-per-lipid have been demonstrated before
272,275
.  Further underscoring 
the role of membrane tension in lipid bilayer integrity, P188 has been demonstrated to 
significantly lower apparent membrane tension and aid restore membrane resealing in 
tetanus toxin-treated cells
84
. As P188 is presumed to only associate with damaged 
membranes
168,201,202
, we hypothesize that increased membrane permeability via increased 
surface tension will lead to increase P188-bilayer interaction. 
 Additionally, hydrophilic pore formation and DPPC membrane rupture have been 
observed to occur under mechanical stress, as reported in an atomic level MD simulation 
study where systematic variation of the bilayer lateral pressure was 
exerted
276
.Hydrophilic pore formation also occurs when a strong transmembrane voltage 
is applied to the membrane, as happens during electrical trauma
277
, leading to loss of 
intracellular homeostasis and eventual cell death. As P188 has been shown in numerous 
studies to prevent the transmembrane passage of enzymes
258
 and various extracellular 
dyes and large molecules by sealing the porated membrane
165,37,181
 , we simulated in a 
second system the interaction of P188 with a bilayer containing a hydrophilic pore to 
evaluate P188’s ability to prevent water molecules to translocate through the membrane.  
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4.2  Systems setup  
 
System 1: Constant surface tension (NPγT ensemble) simulations.  
 
A single P188 molecule was simulated atop a lipid bilayer containing 280 lipids 
(140 per leaflet) DPPC lipids (Figure 1) with the system solvated with TIP3P to 
explicitly simulate water molecules The final unit cell size for the copolymer/DPPC 
bilayer system was 96 x 92 x 70 angstroms, for a total of 55911 atoms, from which 6028 
were TIP3P water molecules and 17 molecules each of Na
+
 and Cl
-
 to neutralize the 
system. Due to the use of periodic boundary conditions and current all-atom membrane 
potential models not being able to maintain appropriate surface areas on long time scales 
in simulations of pure membranes, a baseline surface tension of ~2000-3000 bar/Å is 
recommended for DPPC bilayers to retain normal bilayer structure
275,278
. Surface tension 
(γ) was held constant at 1000, 2000, 3000, 3250 and 3500 bar/Å to simulate the surface 
tension ranges that would induce bilayer compression (< 2500 bar/Å) or lengthening (> 
2500 bar/Å).  
 
Figure 1: Setup of P188-DPPC bilayer system with P188 initial starting position atop the bilayer. 
(Right) Water molecules and salt ions are not shown for clarity. 
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The temperature was maintained at 310K and 1 atm. In terms of simulations 
timescale for model lipid bilayers, it was determined that long simulation times (larger 
than 50 ns) are necessary to distinguish differences in surfaces tensions or equilibrium 
areas and proper sampling of membrane undulations
279
. Simulations for each system were 
therefore run for 150 ns to ensure convergence or until the system became unstable due to 
bilayer collapse.       
 
 
System 2: Simulations of P188 – DPPC lipid bilayer with and without pore induction 
(NPAT ensemble).  
 
A system of P188-DPPC bilayer was generated for simulation at NPAT (constant 
pressure, area and temperature) conditions. The NPAT ensemble is required to prevent 
spontaneous bilayer resealing and to maintain the hydrophilic pore over the course of the 
entire simulation. A DPPC bilayer constituted of 280 lipids (140 per leaflet) was 
generated and a single molecule of P188 was placed atop the bilayer. The system was 
solvated with 7774 TIP3 molecules and neutralized with 22 Na and Cl ions, for a total of 
61159 atoms.  For the hydrophilic pore containing bilayer, the system generated above 
was used and 21 individual lipid molecules were deleted using Schrodinger Maestro 
software to create a pore of diameter ~20 Å (Figure 2).  The system was solvated with 
8533 TIP3 molecules and neutralized with 24 Na and Cl ions, molecules with a final unit 
cell size for the copolymer/DPPC bilayer system of 92 x 90 x 70 angstroms for a total of 
60710 atoms. Both systems were run for 75 ns at temperature of 310K.  
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Figure 2: Setup of P188-DPPC bilayer with a pore system with (left) P188 initial position atop 
the bilayer and water molecules colored in blue, and (right) top view of the pore containing 
bilayer with water molecules not shown for clarity. The pore diameter is ~20 Å. NPAT conditions 
were used to maintain the pore over the course of the simulation. 
 
 
4.3  Results 
 
System 1: Surface tension of the lipid bilayer dictates adsorption or insertion of P188 
 The objective of this system was to obtain atomistic-level mechanistic insights on 
how surface tension affects P188-DPPC bilayer interactions.  We first examined the 
effects of surface tension on the structure and property of the DPPC bilayer by observing 
the area-per-lipid perturbations induced by step-wise modification of surface tension (γ). 
The area-per-lipid reflects the density of lipid molecules in each leaflet of the bilayer and 
is an important parameter to validate simulations against experimentally measured 
values. Here, we used the Visual Molecular Dynamics (VMD) plugin MEMPLUGIN
280
 
to compute the area per lipid over the course of each simulation at various surface 
tensions (γ) (Figure 3).  In each case, the initial starting area per lipid was ~58 Å2, which 
is in agreement with values reported in previous studies of DPPC bilayers
274,279
.   
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Figure 3: Area per lipid of DPPC bilayers at various surface tensions (γ).  The simulation run at γ 
= 3250 (red) became unstable and crashed at 34 ns. 
 
 
 
 (γ) 
(bar/Å) 
Area per lipid +/- S.D.  
(Å
2
) 
1000 54.94 ± 0.48 
2000 56.05 ± 1.15 
3000 59.90 ± 1.62 
3250 70.99 ± 0.45 
 
Table 1: Mean area per lipid over the last 100 ns of simulation at various surface tensions (γ). 
 
 
For each surface tension, the mean area-per-lipid of each simulation is 
summarized in Table 1.  These values are  comparable to those reported in previous 
studies
272,274,275
.  As expected, an increase in γ above 2000 bar/Å led to an increase in the 
area-per-lipid of the bilayer, i.e., increased fluidity and permeability of the bilayer. 
Simulations run at γ= 3500 bar/Å and above became unstable within the first 40 ns and 
could not be continued. These results suggest that there is a critical area per lipid value 
  
 97 
 
(~74 Å
2
) at which the DPPC bilayer starts to collapse. On the other hand, a γ value below 
2000 bar/Å induces bilayer compression and decreases bilayer fluidity.   
 Next, we examined whether the DPPC bilayer’s surface tension influenced P188 
interaction.  For both the γ = 3250 (Figure 4) and γ = 3500 (data not shown) simulations, 
the bilayer lengthened in the x-y phase (as shown by an increase in area per lipid) and 
visual inspection shows that bilayer thickness (z) also decreases with increasing area per 
lipid, indicating increased membrane fluidity. Both the PPO core and the PEO chains of 
P188 start inserting within the first 40 ns of both simulations, with the full copolymer 
residing in the hydrophobic part of the bilayer by 33 ns at γ = 3500 (prior to membrane 
collapse) and 70 ns at γ = 3250.  
 
 
Figure 4: Snapshots taken over the course of the P188-DPPC simulation run at γ = 3250 showing 
insertion of P188 starting at ~40 ns as well as increased area per lipid (x*y) and decreased bilayer 
thickness (z).  The PPO core is colored red and the PEO chains are colored in blue. Lipid tails are 
not shown for clarity.  
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On the other hand, at γ = 3000, the lipid bilayer dimensions do not change 
significantly and it takes a longer time for P188 to start inserting. Initially, only one of the 
PEO chains inserts and PPO core interaction initial interaction and insertion doesn’t start 
until ~55 ns. The full copolymer does not insert until ~80 ns (Figure 5).    
 
Figure 5: Snapshots taken over the course of the P188-DPPC simulation run at γ = 3000 showing 
beginning of insertion of P188 at ~58 ns as well as increased area per lipid and decreased bilayer 
thickness.  The PPO core is colored red while the PEO chains are colored in blue. Lipid tails are 
not shown for clarity. 
 
In contrast, at γ = 2000, the lipid bilayer compresses slightly over time in accord 
with the observed decreased in area per lipid and increased bilayer thickness (Figure 6). 
While part of the PEO chain inserts over the course of the simulation, the rest of the P188 
molecule remains at the water-bilayer interface at γ = 2000. This suggests that the fluidity 
and permeability of the bilayer is too low and presents a steric barrier to copolymer 
insertion.  This is further demonstrated at γ = 1000 where the bilayer is even further 
  
 99 
 
compressed, keeping PEO interaction at the lipid head group level and preventing further 
interaction with the acyl chains of the bilayer (Figure 7). 
Taken together, these simulations show that the surface tension and its effect on 
the lipid packing of the bilayer is an important factor to P188 adsorption and/or depth of 
insertion within the membrane bilayer. Moreover, these data indicate that there is a 
minimum area-per-lipid at which P188 insertion occurs. This aligns well with the 
conclusion of a previous study using lipid monolayers in the Langmuir trough whereby 
P188 is “squeezed” out once membrane integrity and normal surface pressure are 
restored
201
. 
 
Figure 6: Snapshots taken over the course of the P188-DPPC simulation run at γ = 2000 showing 
insertion of the PEO chain and slight compression of the bilayer over time. P188 does not fully 
insert.  The PPO core is colored red while the PEO chains are colored in blue. Lipid tails are not 
shown for clarity. 
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Figure 7: Snapshots taken over the course of the P188-DPPC simulation run at γ = 1000 showing 
slight insertion of the PEO chain and compression of the bilayer over time. P188 does not fully 
insert.  The PPO core is colored red while the PEO chains are colored in blue. Lipid tails are not 
shown for clarity. 
 
 
 Interestingly, and in contrast to what has been previously reported in molecular 
dynamics simulations of copolymers and bilayers
227,281
, the PEO chains do insert into the 
hydrophobic acyl chain region of the bilayer along with the PPO core.  This is not 
surprising as PEO is not purely hydrophilic and is itself considered an amphiphiles
282
.  
 
System 2: 
 In this system, the P188-DPPC bilayer was run at NPAT (constant pressure, area 
and temperature) without and with a hydrophilic pore to investigate P188 interactions 
with a healthy bilayer and one that is damaged and leaky.  
 In the first scenario, P188’s PEO chains intermittently make contacts with the 
polar lipid head groups of the DPPC bilayer but do not insert. The P188 copolymer 
remains in close proximity at the water-lipid interface, with its PPO core consistently 
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shielded from the solvent by its flanking PEO chains (Figure 8). This latter shape is in 
contradiction with coarse-grained models depicting free flowing and seemingly solvated 
PPO and PEO chains
274,281
.  
 
Figure 8: Snapshots of P188-DPPC bilayer simulation run at NPAT conditions without a pore. 
The PPO core is colored red while the PEO chains are colored in blue. Water and lipid tails are 
not shown for clarity. 
 
 However, in the presence of a ~20 Å pore through the DPPC bilayer, P188 inserts 
into the hydrophilic pore at approximately 35 ns into the simulation run (Figure 9).  Once 
again as observed in System 1, the PEO chains, not the PPO core, initially inserts into the 
pore before insertion of the entire copolymer. The initial insertion of the PEO chain into a 
water filled pore makes sense considering the hydrophobicity of the PPO core. We 
hypothesize that the PEO insertion is a “priming” step to allow the hydrophobic PPO to 
remain unexposed to the aqueous solvent before and during insertion into the bilayer.  In 
addition to inserting into the lipid bilayer, P188 prevents water molecules from 
translocating through the pore (Figure 10) thereby effectively acting as a membrane 
sealant.   
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Figure 9: Snapshots of P188-DPPC bilayer simulation run at NPAT conditions in the presence of 
a pore. The PPO core is colored red while the PEO chains are colored in blue.  
 
 
 
 
Figure 10: Snapshots of P188-DPPC bilayer simulation run at NPAT conditions in the presence 
of a pore. Water molecules are shown in light blue. The PPO core is colored red while the PEO 
chains are colored in blue.  
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4.4  Discussion 
 
This study is, to our knowledge, the first all-atomistic MD simulation 
investigation of P188-bilayer mechanism of interaction. Our main new findings show that 
P188 adsorption at the lipid-head group region, compared to insertion inside the 
hydrophobic tail region of the bilayer, depends on the area-per-lipid, i.e. the permeability, 
of the membrane.  Increases in the area-per-lipid via increases in applied surface tension, 
or induction of a hydrophilic pore, lead to an increased rate of insertion of P188.  In 
contrast, reduction of area -per -lipid prevents P188 insertion, with the closely packed 
lipids maintaining P188 in an adsorption state. Moreover, we observed that the generally 
considered “hydrophilic” PEO chain, also inserts at high membrane permeability, in 
contrast to earlier studies reporting that the flanking PEO chains remain at the lipid head 
group level
227,281
. 
Experimental biophysically-based studies examining P188 interactions with 
synthetic lipid membranes propose a two-state mechanism of block copolymer 
interaction: initial adsorption followed by insertion into the lipid membrane
169
. Our 
simulations show that adsorption vs. insertion is dependent on the integrity of the 
membrane, with area-per-lipid affecting the rate at which P188 inserts into the bilayer, 
rather than adsorb at the head-group region. 
Increases in surface tension of the DPPC bilayer induces changes in the structural 
properties of the bilayer, such as increases in its area per lipid and lateral diffusion 
coefficients of its lipid molecules, and decreases in lipid order parameter and thickness of 
the bilayer
274
. Altogether, these changes increase the fluidity and permeability of the 
bilayer. We therefore used an increase applied surface tension on a DPPC bilayer as a 
molecular mimic of membrane stretching and damage.  Our study was based in part on 
seminal biophysical studies that demonstrated using synthetic lipid monolayers that P188 
and other membrane stabilizing copolymers insert into injured regions of membranes 
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when surface pressure is reduced and gets “squeezed-out” when membrane integrity is 
restored
201,202
.   
At optimal surface tension γ (in the case of a DPPC bilayer simulated using 
Desmond force field parameters, optimal γ = ~2000 bar/Å), the membrane is in a state in 
which attractive interactions between its lipids hydrocarbon chains and the repulsive 
interactions between their head groups are in balance, resulting in optimal lipid packing 
density and a free energy minimum with respect to its surface area
283
. As observed in our 
results, while the PEO chains of P188 make contact and interact with the lipid head 
groups of the bilayer and even insert into the hydrophobic region of the bilayer, the PPO 
core is sterically hindered from entering the bilayer   
However, as γ deviates from this optimal value, the bilayer will either shrink or 
expand, altering the structural properties of the bilayer in response
272,274
.  As expected, 
further compression of the bilayer at γ = 1000 prevents further PEO insertion into the 
bilayer, limiting its interaction at the polar head group level.  In contrast, expansion of the 
bilayer at γ = 3000 or above leads to spreading of the lipids and eventual insertion of 
P188, with the time of insertion occurring earlier at higher γ. These results underscore the 
dependence of copolymer insertion on area per lipid, with increased area per lipid of the 
bilayer lowering the penetration barrier. This is further demonstrated in system 2 when 
comparing a healthy membrane run with its area kept constant using the NPAT ensemble 
to a membrane with a hydrophilic pore. While the PEO chains of P188 make contacts 
with the head group region of the healthy lipid bilayer, insertion does not occur in the 
timeframe of the simulation.  In contrast, presence of a pore drives the copolymer to 
insert and block translocation of water molecules from one side of the bilayer to the 
other, effectively sealing the bilayer pore.  
Our findings that the PEO chains insert along with the PPO core at increased area 
per-lipid-are in apparent contradiction with previously reported coarse-grained reports of 
copolymer-bilayer interactions showing that only the PPO core is capable of inserting 
into the bilayer, with the PEO chains being restrained to the head-group region at the 
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membrane-water interface
227,281
.   However, insertion of PEO into the bilayers should not 
be surprising as PEO also possesses some hydrophobic character
284
. At high degree of 
hydration in an aqueous environment such as outside the membrane, PEO is highly 
hydrophilic. However, at a low degree of hydration such as in the hydrophobic region of 
the bilayer, PEO becomes relatively more hydrophobic
284
. This has been further 
demonstrated in a an experimental and computational study showing that addition of 
NaCl, which is present in our system at physiological concentration, decreases PEO block 
solubility in aqueous solution
285
. Moreover, a previous study has found that at a lower 
lipid order, PEO chains can enter the hydrophobic region of a bilayer, whereas they are 
excluded in higher-order phases
286
. Spontaneous entry of pure PEO into the hydrophobic 
region of a DMPC bilayer after overcoming the outer leaflet head-group region has also 
been demonstrated previously using atomistic MD simulations
208,226
. These studies 
concluded that PEOs interacting with the hydrophobic tails inside the bilayer is a 
consequence of strong Lennard-Jones interaction energy between the polymer and the 
tails, and this is also responsible for PEOs contrasting hydration behavior in aqueous 
media as compared to a hydrophobic environment.   
We established in chapter 2 and 3 that along with P188, there are other PEO-PPO-
PEO triblocks and PEO-PPO diblocks that interact with membranes in order to either 
stabilize or destabilize them.  Studies using Langmuir isotherm and fluorescence 
microscopy experiments using a synthetic lipid monolayer spread at the air-water 
interface in the presence of injected poloxamers of varying architectures showed that a 
longer hydrophobic block caused the copolymer to be less soluble and in more polymer 
adsorbed to the interface
167
 as well as in stronger penetration.  Lateral compression of the 
monolayer squeezes out copolymers at different pressures depending on the interplay 
between both PEO:PPO ratio and total size of the copolymer, with lower PPO:PEO ratio 
and smaller polymer sizes resulting in lower squeeze-out pressure and thereby lower 
maintenance within the monolayer
167
 Membrane insertion appears to be highly dependent 
on the PPO/PEO ratio of the block copolymer, with hydrophobic dominant poloxamers 
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(PPO/PEO > 1) capable of inserting and subsequently permeabilizing the cell 
membrane
167,169
.  Another study has shown that copolymers that contain a PPO block 
length comparable to the bilayer thickness tends to percolate across the lipid bilayer 
while copolymers with a shorter PPO block length only partially insert into the 
membrane with the PEO blocks remaining in the solvent
281
.  Using all-atomistic MD 
simulations and varying applied surface tension on the bilayer will allow for further 
probing of architectural and compositional differences in membrane stabilization 
efficacy, in particular, how substitution of terminal end groups on a diblock architecture 
affects its bilayer interaction. 
 Finally, the constituent of a biological bilayer affects its properties.  Biological 
cell membranes are composed of a complex assortment of lipids and proteins distributed 
asymmetrically to the outer and inner leaflets. Furthermore, the lipid composition of the 
dystrophic muscle membrane differs from that of a healthy muscle membrane 
composition
248
. The goal of future MD studies will be to more closely mimic muscle 
membrane lipid compositions to determine how they affect copolymer interaction. 
 
 
4.5  Perspectives 
 
 All-atomistic MD simulation is an extremely powerful tool providing molecular 
level insights into the mechanism of copolymer-bilayer interaction. Moreover, it allows 
for sensitive modulation of the architectural and compositional parameters of the 
copolymer, as well as biophysical parameters of the bilayer to mimic in vitro injury 
systems. Finally, computational simulations allow for relatively quick design and testing 
of copolymers-bilayer interaction to guide optimal membrane stabilization synthesis. 
With this approach we have obtained new insights into the fundamental basis of 
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copolymer-membrane interactions that are key to understanding the membrane 
stabilization function of poloxamers. 
 
 
4.6 Methods 
 
Software package and high performance computing. The Schrodinger modeling suite 
and the Desmond molecular dynamics simulation package were used for the modeling, 
simulation, and analysis. Each simulation was carried out using 400 or 600 parallel 
computing cores on the Mesabi supercomputer at the Minnesota Supercomputing 
Institute, a Hewlett-Packard high-performance supercomputer with a LINUX operating 
system that consists of 8,728 compute cores and 24 TB of random-access-memory.  
 
Building copolymer systems: Using Maestro, the graphical user interface of the 
Schrodinger modeling suite package, each PEO and PPO subunits was built, duplicated, 
and linked to generate a P188 molecule (PEO75-PPO30-PEO75). All subunits were 
numbered and colored by hydrophobicity (red) and hydrophilicity (blue). Each of the 
built copolymers was then energy minimized using the OPLS 2005 force field run by a 
truncated Newton algorithm for at least 10,000 steps to allow collapse of the built linear 
copolymer structure to its more globular-like representative conformation.  
 
Building copolymer-phospholipid membrane systems: System Builder in Desmond was 
used to build the simulation box consisting of the energy-minimized copolymer placed 
atop a DPPC phospholipid bilayer membrane and solvated using TIP3 water molecules. 
To create a hydrophilic pore for System 2, individual phospholipid molecules were 
deleted to form a transmembrane pore of ~20Å diameter.    
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Setup of molecular dynamics simulations: Each simulation was carried out under 
constant temperature (310 K) and constant pressure of 1 atm at 2 fs timestep using the 
OPLS 2005 force field. Constant surface tension simulations were performed in the NPγT 
ensemble (constant pressure, constant surface tension and constant temperature). 
Simulations of the systems evaluating a membrane pore were run using the NPAT 
ensemble to maintain the pore and prevent collapse of the system. Simulations were 
carried out using a default initialization protocol included in the Desmond simulation 
package with gradual heating to the targeted temperature (9). A snapshot at every 1 ps, 
equivalent to 500 fs timesteps, was collected over the course of the simulation for 
analysis.  
 
Analysis: The collapse or expansion of the copolymer was monitored by examining 
changes in area-per-lipid of the DPPC bilayer. Event Analysis module in Desmond was 
used to area-per-lipid for each simulation. Visual Molecular Dynamics (VMD) 
MEMBRANEPLUGIN tool was used for bilayer structural analysis
280
.   
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CHAPTER 5 
SUMMARY 
 
 The central objective of this work was to investigate the mechanisms of 
copolymer-based membrane stabilization to protect striated muscle membranes in the 
context of Duchenne Muscular Dystrophy (DMD) using a structure-function approach. 
While there have been numerous studies investigating the use of synthetic triblock 
copolymers as membrane stabilizers for various pathophysiological conditions of cell 
membrane injury
165,287,179,264,184,175,288,185,289
, there has, at the beginning of this project 5 
years ago, only been a handful of studies looking at copolymer-based membrane 
stabilization in the context of DMD
37,187,188,194
.  Most of these studies focused on treating 
the cardiomyopathy of the disease, leaving efficacy on the skeletal muscle pathology 
unclear. Additionally, these studies focused on the use of one particular copolymer, 
Poloxamer 188, which is only one of an exponentially large copolymer chemical 
landscape. This work highlights structure-function studies to fundamentally dissect, for 
the first time to my knowledge,  how the mechanism of membrane interaction and 
stabilization is impacted by critical molecular properties of copolymers including 
architecture, composition and chemistry. As such, the overarching theme of this work 
aimed to investigate the optimization of membrane stabilizing copolymers for DMD 
using in vitro, in vivo, and in silico methods.   
 
 
P188 is protective in the context of both DMD cardiomyopathy and skeletal 
pathology 
  
 Prior to this work, the effects of P188 on the DMD skeletal myopathy have been 
uncertain
187,194,189
.  In Chapter 2: “Membrane-stabilizing copolymers confer marked 
protection to dystrophic skeletal muscle in vivo”, an in vitro membrane-injuring hypo-
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osmotic stress assay was developed and optimized to screen for membrane stabilization 
efficacy of P188 and other triblock copolymers in dystrophic skeletal muscle cells. The 
results obtained using this assay establish that P188 is efficacious at preventing hypo-
osmotic stress-induced enzyme release in vitro using a copolymer concentration that was 
demonstrated to be efficacious in stabilizing the membrane of mdx cardiomyocytes. 
Based on these results, I concluded that P188 can stabilize dystrophic skeletal muscle 
membranes and that the lack of in vivo efficacy observed in previous studies was not due 
to a differential effect of P188 on skeletal vs cardiac lipid membranes but rather due to 
the pharmacokinetics and pharmacodynamics of the molecule once injected in vivo.  
For the first time, this work establishes that P188 efficacy in protecting against 
lengthening contraction-induced force loss is crucially dependent on route of delivery.  
Furthermore, a larger triblock copolymer of equivalent PPO/PEO composition also 
showed efficacy at lower dosage but also showed differential pharmacodynamics. This is 
another proof-of-principle result that copolymer-based membrane stabilizers can be 
optimized beyond the P188 structure. 
Chapter 2 established proof-of-principle that membrane stabilizing copolymers 
protect dystrophic skeletal muscles in vivo.  The long-term goal would be to incorporate 
these findings with recent studies of P188 preserving cardiac
37,187,188
 and respiratory 
function
195
 to ultimately guide potential clinical application to treat all striated muscles in 
DMD patients.  Because P188 has already been administered for human use for other 
conditions, it has already passed extensive pharmacokinetics and ADME studies to 
validate clinical safety
176,198
.  It will be critical to perform long-term studies in small and 
large animal models of DMD to establish the pharmacokinetics and optimal 
pharmacodynamics of P188 and assessing protection following both acute and chronic 
treatment.  
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A PEO-PPO diblock architecture is sufficient for membrane stabilization 
and PPO end group modification significantly affects in vivo efficacy 
 
To my knowledge, no work has been performed to assess copolymer based membrane 
stabilization beyond the PEO-PPO-PEO triblock architecture. The work performed in 
Chapter 3:"Structure-function relationship of membrane stabilizing diblock copolymers” 
demonstrates for the first time that a PEO-PPO diblock architecture is sufficient in 
stabilizing injured biological membranes. This result is significant as a diblock 
architecture allows for easier exploration of the copolymer chemical landscape due to 
simpler synthesis process and, importantly, the ability to modify the terminal end group 
of the hydrophobic PPO core for optimized membrane insertion and anchoring. 
This latter capability is substantial as it allows for fine-tuning of the PPO 
interaction at the membrane. As exciting proof-of-principle, substitution of a hydrophobic 
tert-butoxide group to the PPO block of two compositionally different PEO-PPO diblocks 
significantly improved their membrane stabilization efficacy in vivo.  Based on these new 
findings we propose an "anchor and chain" model whereby the PPO block inserts into the 
hydrophobic alkyl tail region of the injured membrane and is stabilized or “anchored” 
there by its terminal tert-butoxide group. A PEO chain of sufficient length to maintain the 
diblock copolymer relatively hydrophilic is required to prevent complete insertion and 
permeabilization of the membrane. 
The ability to modulate diblock copolymer-membrane interaction via chemical 
alteration of diblock molecular properties eases access to a vast chemical landscape to 
design optimized membrane stabilizers that can be first screened in vitro using the hypo-
osmotic assay optimized in Chapter 2.  Furthermore, substitution of the actual PPO 
block with other hydrophobic chemical moieties such as polybutylene oxide (PBO) is 
another avenue worth exploring in future studies. These are the focus of future studies. 
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Development of an all-atomistic Molecular Dynamics system to assess 
copolymer-bilayer interactions in silico 
 
 Significant advances in the field of computational modeling now allow for 
investigating complex biological systems at faster speeds and lowered computational 
cost.  MD simulation methods have become a powerful array of tools to investigate the 
complex structural and dynamical behaviors of polymers and lipid membranes that are 
difficult to probe experimentally at a molecular level. Chapter 4: “All-atomistic 
Molecular Dynamics investigation of block copolymer-lipid membrane interactions” is 
the first demonstration of all-atomistic simulations for evaluation of P188-DPPC bilayer 
interactions. Using increases in surface tension applied to the lipid bilayer, an area-per-
lipid dependence of adsorption vs. insertion was uncovered, supporting previous 
monolayer studies showing that P188 inserts into areas of decreased lipid density and 
gets “squeezed-out” once membrane integrity is restored202.  Another new finding that 
resulted from this study is the observation that one or both PEO chains of the triblock 
initiate insertion of the copolymer. This is in contrast to previous computational studies 
and models using coarse-grained models that depict the PEO chains remaining at the lipid 
head group interface. This is not a surprising finding as PEO hydrophobicity is modulated 
by its hydration level, which likely differs inside the membrane compared to the bulk 
solvent
284,285
. This new observation suggests that the copolymer prefers to minimize its 
solvent accessible area, particularly to its more hydrophobic PPO group, by using its PEO 
chains to shield the PPO group from water. Testing this hypothesis by calculating the 
solvent accessible surface areas for the whole copolymer and its individual blocks is a 
focus of future work. Furthermore, other parameters can be obtained from MD 
simulations, such as lipid tail order, bilayer thickness, and radii of gyrations, which are 
key factors to fully understand copolymer, bilayer, and copolymer-bilayer behaviors.   
 In future studies, these newly developed computational approaches will allow to 
theoretically assess how copolymers of varying architecture, sizes, and chemical 
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compositions interact with a bilayer. This is extremely powerful as it allows to more 
intelligently guide design and synthesis of optimized copolymer molecules for in vitro 
and in vivo testing.   
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CHAPTER 6 
THOUGHTS AND PRELIMINARY DATA FOR FUTURE DIRECTIONS 
 
 
 In addition to the corpus of work summarized above, as well as the potential 
future studies that can stem from each chapter of this thesis, several other endeavors have 
been started to further our understanding of copolymer membrane stabilizers as potential 
therapeutics.  Some of the very preliminary results and thoughts obtained from these 
studies are summarized below.  
 
 
6.1 Cardiac stress-test studies to screen copolymers for cardiac membrane 
stabilization 
 
 P188 has been well-established to be cardioprotective in the context of beta-
adrenergic stress in dystrophy
37,187,234
 and we demonstrated in Chapter 2 that it is also 
protective in the context of skeletal muscle lengthening contraction injury.   Because of 
the interplay between progression of DMD cardiomyopathy and the skeletal myopathy as 
a “pathophysiological load” on the heart, it is important to evaluate other candidate 
membrane stabilizers to validate their effectiveness in both cardiac and skeletal muscle.  
Moreover, due to the differential effects of delivery routes on pharmacodynamics in vivo, 
it is important to determine whether differential routes of delivery can target both the 
heart and skeletal muscles concurrently.   
 The efficacy of both intravenous and intraperitoneal delivery in protecting the 
dystrophic myocardium is known. On the other hand, neither of these delivery routes 
effectively targets the hind-limb skeletal muscles, which we demonstrated that 
subcutaneous delivery was optimal for.  It was therefore important to determine whether 
or not subcutaneous delivery would also be as effective for the heart. To test that, we 
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used an isoproterenol stress in mdx mice receiving either saline or 460 mg/kg P188 subQ 
or IP (Figure 1).  While the Kaplan-Meier statistics showed no significant difference 
between the saline and P188 groups over the course of the 60 hours protocol, results 
indicate that both IP and subQ delivery of P188 appear to be protective over the first 24 
hours of the challenge in contrast to the saline treated mdx group which had over 40% 
mortality within that timeframe. This challenge protocol could be shortened in future 
studies for faster screening of other copolymer architectures, dosages, and delivery 
routes.  
 
 
Figure 1:  Survival study of mdx mice subjected to isoproterenol stress in the presence or 
absence of 460 mg/kg P188.  Mdx mice were injected with 10 mg/kg isoproterenol IP 3x/day and 
simultaneous P188 treatment was given at the same time as the first and last isoproterenol 
injections of the day. BL/10 group served as control and were given saline IP.  N = 7-8 mice per 
group.  
 
 It will be important in future studies to establish the cardiac efficacy of the tert-
butoxide diblocks and other potential membrane stabilizing copolymers that are found to 
be protective in skeletal muscle to further probe whether routes of delivery in vivo would 
differentially target the heart and the limb muscles.  The goal would be to optimize 
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membrane stabilizers that target both systems and that could be delivered chronically, 
such as via subcutaneous pumps that are commonly used clinically for diabetic patients.  
 
 
6.2 Exploration of block lengths, overall hydrophobicity, and block moieties for 
membrane stabilization  
  
 We have demonstrated in Chapters 2 and 3 that both triblock and diblock 
architectures can function as membrane stabilizers. As mentioned previously, the 
synthetic chemical landscape available is incredibly vast.  Therefore, an intelligent 
approach toward structure-function screening needs to be undertaken to discover what the 
critical chemical parameters for membrane stabilization are. For example, triblock and 
diblock architectures have been investigated in this work.  We determined in Chapter 3 
that a triblock architecture is not necessary for membrane stabilization.  Moreover, we 
discovered that fine-tuning of the functional end group on the PPO block significantly 
altered membrane stabilization efficacy leading to an “anchor and chain” model of 
membrane stabilization. We hypothesize that this hydrophobic end-group anchors the 
copolymer inside the hydrophobic bilayer while the presence of the PEO chain prevents 
the copolymer from fully inserting through to potentially permeabilizing the membrane. 
As a focus of future studies, it will be important to determine how the hydrophobicity of 
this PPO end group and of the hydrophobic block overall affects membrane insertion.  
Perhaps this terminal end group could be further optimized by making it slightly more 
hydrophobic by extending it and/or adding extra methyl groups. 
We and others have shown that PPO/PEO ratio is important in controlling 
stabilization vs. lysis of the membrane
164,208,258
. We also demonstrated that the 0.20 
PPO/PEO ratio of P188 is not necessarily the “sweet spot” in membrane stabilization, as 
we observed protective effects of a diblock with 0.30 PPO/PEO ratio in Chapter 3. It 
will be important to determine the PPO/PEO ratio range that is needed for membrane 
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stabilization, as it will determine the ratio in blocks lengths when designing a copolymer.  
Furthermore, it is also necessary to determine if there is an optimal PPO block length for 
membrane stabilization.  Synthesis and screening of diblock copolymers of varying PPO 
block lengths and associated PEO chain lengths to maintain the PPO/PEO ratio within 
membrane stabilization range could be an exciting and important future step in the 
structure-function study of diblock copolymers.  
Beyond tuning PPO block lengths and functional end groups, it would be 
interesting to explore substituting the PPO block itself with a different hydrophobic 
moiety, such as polybutylene oxide.  Other architectures, such as reversed triblocks (A-B-
A and B-A-B) as well as sequential copolymers (A-B-A-B…) could also be explored.  To 
do so, the hypo-osmotic stress assay used in this work needs to be optimized for higher 
throughput screening in 96 or more well plates.   
 
  
6.3 Labeling of P188 for fluorescence imaging 
 
 While many biophysical and physiological studies have made P188 interaction at 
the membrane interface an accepted model, actual experimental observation using 
microscopy techniques is still lacking. Fluorescent labeling was chosen over alternative 
labeling strategies, such as radioactive and heavy metal labeling, due to easier handling 
and conjugation. The hydroxyl end groups on the PEO chains of the P188 are reactive 
groups that can be chemically substituted for functionality with fluorescent tags.  Several 
different fluorescent labels have been considered so far. A Rhodamine-B derivative was 
first chosen as a lower-cost alternative for bulk volume infusions necessitated by large 
animal in vivo studies, ease of detection, and known synthetic method. Alternatively, the 
far-red fluorescent dye Alexa Fluor 647 was chosen as another test label due to its ease of 
conjugation and low membrane interaction factor
290
. 
 
  
 118 
 
Tagging of P188 with Rhodamine B 
 
 The Rhodamine B derivative synthesis and labeling with P188 was performed by 
Wenjia Zhang, a graduate student in Prof. Frank Bates in CEMS at the University of 
Minnesota.  Briefly, Rhodamine B base (Sigma, St. Louis, MO) was transformed to 
Rhodamine B acide chloride and reacted with the hydroxyl-terminated PEO chains of 
P188 to yield RhB-P188 (Figure 2). A tagging efficiency of ~1.6 dye molecules per P188 
was estimated using calibration curves at Rhodamine absorption wavelength of 556 nm. 
 
 
Figure 2: RhB-P188. Poloxamer 188 labelled at both PEO blocks terminal hydroxyls with 
Rhodamine B. (Figure obtained from Wenjia Zhang). 
 
Preliminary imaging experiments of RhB-P188 using confocal microscopy 
 
 The confocal microscopy imaging was performed by D’Anna Nelson, a graduate 
student, as part of her rotation project under my mentorship.  As a first pass experiment, 
HEK cells were subjected to a 15 second distilled H2O hypo-osmotic stress in the 
presence or absence of RhB-P188.    
Visualization was performed using confocal microscopy at the University 
Imaging Center (UIC).  As seen on Figure 3, the RhB-P188 appears to localize at the 
periphery of the cells suggesting membrane labeling. However, labeling was observed in 
both stressed and unstressed conditions, indicating non-specific interaction with the cells. 
This was further confirmed when addition of pure rhodamine dye to unstressed HEK 
cells still led to intense labeling signals (data not shown).  This result is not surprising 
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considering the innate hydrophobicity of rhodamine itself. A recent study has 
demonstrated that hydrophobicity of a dye is the major determinant of non-specific 
binding
291
.  
  Another study examining non-specific membrane interaction of a range of water-
soluble fluorophores exposed to unilamellar lipid vesicles found that another rhodamine 
derivative, Sulforhodamine B, has a high membrane interaction factor
290
.  However, this 
study also showed that another red shifted fluorophore, Alexa Fluor 647 (640 nm 
excitation), has a relatively insignificant membrane interaction factor, making it an 
arguably better label candidate to test.  
 
Figure 3: RhB-P188 labels both stressed and unstressed HEK cells. HEK cells were subjected 
to 25 minute incubation with 150 uM RhB-P188. The label-containing media was then replaced 
with dye-free media for imaging. Red channel and brightfield images were then taken under 
normal isotonic conditions (top panels) and under hypo-osmotic stress (bottom panel).  Label-
containing media was replaced with dye-free media for imaging. 
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Tagging of P188 with Alexa Fluor 647 dye 
 
 To label P188 with Alexa Fluor 647, a copper-free click chemistry approach was 
chosen. Conjugation of the Alexa dye necessitated azide-functionalization of the terminal 
end groups of the copolymer.  This synthetic step was designed and performed by Dr. 
Karen Haman, a collaborating former graduate student in Dr. Frank Bates group in 
CEMS.  Briefly, azide-functionalization of P188 required tosylation of the normally 
hydroxyl-terminated P188 followed by reaction with sodium azide to substitute the 
tosylated end groups with azide.  The product was characterized with NMR and FTIR to 
ensure successful azide substitution.   
 To generate the Alexa Fluor 647-P188, the copper-free click reagent Alexa Fluor 
647 DIBO alkyne (Invitrogen, Carlsbad,CA) was reacted in 1.5x molar excess with 
azide-functionalized P188 at room temperature in the dark, overnight.   
 
Preliminary imaging experiments of AlexaFluor647-P188 using confocal microscopy 
 
 The confocal microscopy imaging was performed by D’Anna Nelson, a graduate 
student, as part of her rotation project under my mentorship. Based on the high non-
specific labeling observed using the rhodamine-B tagged, the first control experiment was 
to determine whether or not incubation of HEK cells with the AlexaFluor 647 probe 
alone would result in non-specific interaction. As seen on Figure 4, the AlexaFluor647 
label itself does not appear to non-specifically bind to HEK cells. Labeling of dead 
rounded cells is observed. 
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Figure 4: Alexa Fluor 647 label alone does not label HEK cells. Red channel and brightfield 
images taken after 10 minute incubation with 150 uM Alexa Fluor 647 under normal isotonic 
conditions (top panels) and under hypo-osmotic stress (bottom panels).  Label-containing media 
was replaced with dye-free media prior to imaging. 
 
We next visualized the Alexa Fluor 647-P188 conjugated molecule in HEK cells 
undergoing a hypo-osmotic stress (Figure 5).  Except for dead rounded cells, no labeling 
signal was observed. These preliminary results raise several hypotheses: 1) it is possible 
that any membrane-specific interaction is too weak and that any potential tagged P188 is 
detached and washed away during media replacement; 2) while the Alexa Fluor 647 
fluorophore has been determined to have low membrane interaction
290
, attachment of the 
bulky and still relatively hydrophobic Alexa Fluor 647 molecule (MW = 1500 g/mol) on 
potentially both ends of the P188 copolymer (MW = 8400 g/mol) could certainly affect 
the copolymer’s interaction with lipid bilayers. Our work in Chapter 3 demonstrate that 
fine tuning of terminal end-groups of a diblock copolymer can significantly affect 
membrane interaction capacity, and it would be overly optimistic to think that attaching a 
large fluorophore at the ends of the copolymer would be completely inconsequential. 
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Figure 5: Alexa Fluor 647-P188 labels shows no labeling signal under hypo-osmotic stress in 
HEK cells. Red channel and brightfield images taken after 25 minute incubation with 150 uM 
Alexa Fluor 647 -P188 under normal isotonic conditions (top panels) and under hypo-osmotic 
stress (bottom). Label-containing media was replaced with dye-free media prior to imaging. 
 
 In summary, it remains unclear whether there is a fluorophore that combines both 
ease of synthesis and labelling with low effect on actual copolymer-membrane 
interaction.  Another potential approach and subject of future studies would be to use 
radiolabeling of the copolymer for in vivo tracking purposes, as it has been done in 
previous pharmacokinetics studies of P188
196
.  
 
 
6.4 Electromyography analysis of membrane stabilizing copolymer treated mdx 
mouse during lengthening injury in vivo  
  
It is well-established that mechanical stress during lengthening contraction 
disrupts muscle membranes, more notably so in DMD
96
. Along with maintaining cellular 
homeostasis by acting as a barrier, the cell membrane is also responsible for propagating 
action potentials from the neuromuscular junction, along the myofibers and down to the 
transverse-tubules.  It has therefore been hypothesized that excitation-contraction 
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coupling at the level of the muscle membrane would be affected in dystrophic muscle, 
particularly in the context of the membrane damaging lengthening contraction injury. 
Studies have shown that dystrophic muscle fibers have depolarized membrane potentials, 
implicating impaired action potential generation and/or propagation and potentially 
impaired ion movement homeostasis
292–295
. Electromyography (EMG) analysis of 
dystrophic mdx muscle during lengthening contractions reveal impairment in the 
generation and conduction of action potentials as observed in significant decrease in M-
wave root mean square (RMS)
225
.  Furthermore, it was observed that mdx muscle fibers 
are depolarized post-injury, in contrast to post-injury fibers from control mice which 
retain normal resting membrane potential. These observations were not seen in mdx mice 
performing concentric contractions indicating that impairment in action potential 
generation and/or propagation is a direct result of lengthening contraction injury rather 
than other muscle force loss causing factors such as fatigue. 
One hypothesis is that lengthening contraction injury impairs maintenance of the 
electrochemical gradient by disrupting intracellular homeostasis via injury-induced 
increased membrane permeability. To test this hypothesis, we performed a very 
preliminary study where we used a membrane stabilizer copolymer to stabilize the 
membrane during in vivo lengthening contractions while simultaneously performing 
EMG analysis in order to assess whether a stabilized membrane would prevent a loss in 
M-waves RMS. This study was performed in collaboration with Dr. Dawn Lowe from the 
Physical Therapy and Rehabilitation Science department at the University of Minnesota. 
Dr. Lowe performed the surgical implantations of the electrodes necessary for EMG 
measurements. 
The electrodes were implanted in the TA muscles of mdx mice as described 
previously
296
. Briefly, mice were anesthetized using isoflurane and the distal ends of two 
platinum-iridium electrode wires with de-insulated ends were passed through a 26-gauge 
needle beneath the superficial fascial sheath of the TA so that the wires lay 2 mm apart. 
This spacing allows for sampling of the M-wave activity from the entire TA muscle. The 
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proximal ends of the wires were run subcutaneously to the dorsal cervical region and 
through the skin to be connected to an EMG amplifier during the actual experiment. Mice 
were allowed to recover for 10 days before testing. 
30 min prior to testing, mdx mice were injected intraperitoneally (IP) with either 
saline vehicle, or 1000 mg/kg copolymer. Because this was a very preliminary study, the 
copolymer used in this study is a triblock copolymer of equivalent PPO/PEO ratio as 
P188 but of smaller molecular weight.  While not mentioned previously in this work, this 
copolymer has also demonstrated in vivo efficacy using 1000 mg/kg IP injections in a n = 
5 mdx mice group (data not shown). 
Very preliminary results (n = 1 for copolymer treated group) suggest that 
copolymer based-membrane stabilization reduces M-wave RMS decreases during a 
lengthening injury protocol (Figure 6).  If confirmed under rigorous further study, this 
would support the hypothesis that the impairment in action potential 
generation/conduction occurs at the membrane level upward of the intracellular 
contractile machinery.  While these are very preliminary results and a larger group of 
treated animals need to be further tested, we can speculate about the mechanisms 
underlying this impairment. Previous findings that injured fibers are depolarized post 
lengthening injury
225
 suggest the involvement of ion channels at the membrane, such as 
stretch and voltage activated Na
+
 and Ca
2+
 channels, as well as increased transmembrane 
influx and outflow of ions due to increased membrane permeability.  
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Figure 6: Torque and M-wave in mdx mice treated with saline or membrane stabilizing 
copolymer.  (A) Force loss and M-wave RMS of the anterior crural muscles, in adult mdx mice 
treated with saline (n = 4) or 1000 mg/kg copolymer (n =1) intraperitoneally at least 30 min 
before the injury protocol, was assessed over the course of 50 lengthening contractions.  Force 
loss and M-wave RMS  is presented as a fraction of the initial maximal force +/- S.E.M. (B) 
Postinjury isometric torque and RMS recovery. (C) Representative M-wave tracings at 
lengthening contraction#1 and #50 for saline and copolymer treated mdx mice.  
 
Impairment in the tightly regulated electrical gradient could lead to the reported 
observed increased Na
+
 and Ca
2+
 concentrations inside cells and dysregulation of the 
activity of channels that are part of that electrochemical cascade. Moreover, sustained 
depolarization of individual fibers renders them unexcitable and less likely to contribute 
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to force production. Copolymer-based membrane stabilization could therefore play a role 
in preventing transmembrane leaking of ions and help maintain normal resting membrane 
potential.  More work could be done to dissect this mechanism of impaired action 
potential generation/conduction including measuring resting membrane potentials of 
injured myofibers in the presence of membrane stabilizers and membrane channel 
blockers to tease apart specific contributions to the deficit. While the total force deficit 
observed during lengthening contraction injury in DMD is likely the result of multiple 
factors, the purpose of this study is to tease apart the specific contribution of the impaired 
electrophysiology and to potentially relate it to the concurrently observed loss of 
intracellular homeostasis. 
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FINAL REMARKS 
 
 
This whole body of work is the final product of an interdisciplinary and 
collaborative approach to further understanding how to optimize synthetic copolymers for 
biomedical application in the context of Duchenne Muscular Dystrophy. Collectively, the 
results obtained in this dissertation work has highlighted and addressed several gaps in 
knowledge in the field.  These include issues of in vivo delivery for optimal efficacy, a 
first mechanistic investigation of block copolymer architecture and chemistry, and 
finally, the development of a computational tool to probe mechanism of interaction at a 
biophysical level.  It represents a significant advancement to what is a relatively new area 
of research and discovery and hopefully furthers the potential clinical application of a 
line of medically-relevant polymer chemistries. 
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